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ABSTRACT
Adriamycin is an important anticancer agent. However, the clinical use of 
Adriamycin is limited by its undesirable side effects, especially cardiotoxicity. One of 
the most likely mechanisms of Adriamycin toxicity is the production of reactive oxygen 
free radicals. Catalase is a major enzyme involved in detoxification of hydrogen peroxide 
(H20 2) in mammalian cells. It has been shown that catalase activity per g tissue of the 
heart is very low in comparison to other tissues, being only about 2% that of liver in the 
mouse. This less proficient ability to dispose of reactive oxygen species may be 
responsible for the high sensitivity of the heart to Adriamycin toxicity. This dissertation 
research was thus designed to test this hypothesis.
Transgenic technique was applied to produce cardiac catalase overexpressing 
transgenic mice. A transgene for overexpression of catalase in the heart was constructed. 
This transgene contained the alpha cardiac myosin heavy chain promoter, the rat catalase 
cDNA, and polyadenylational sequence. This transgene was modified and injected into 
mouse embryos. The embryos were implanted into pseudopregnant females and allowed 
to come to term. The transgenic mice were identified using Southern blot, Dot blot, and 
polymerase chain reaction (PCR) procedures. Catalase activities and mRNA 
concentrations in the heart and other organs were measured. Fifteen healthy transgenic 
mouse lines were produced.
xm
Catalase activity was overexpressed specifically in the heart, ranging from 2- to 
630-fold higher than normal. Other antioxidant systems were not altered in the transgenic 
heart. The transgenic mice were used to determine the effect of catalase activity on acute 
and chronic cardiotoxicities of Adriamycin. In the acute studies, the isolated mouse atria 
were incubated with Adriamycin and changes in contractile force and heart rate were 
recorded as a measurement of cardiotoxicity. Changes of cardiac lipid peroxidation and 
serum creatine phosphokinase (CPK) activity in the mice treated with Adriamycin at 20 
mg/kg body weight were also measured. In the chronic studies, both transgenic mice and 
controls were repeatedly treated with low doses of Adriamycin. Myocardial 
morphological changes were measured. As compared to normal controls, transgenic 
lines expressing catalase activity 60- or 100-fold higher than normal exhibited dramatic 
resistance to Adriamycin-induced cardiac lipid peroxidation, elevation of serum creatine 
phosphokinase, and functional changes in the isolated atrium. The transgenic mice were 
also highly resistant to cardiotoxicity induced by chronic treatment of Adriamycin. In 
addition, catalase overexpression suppressed hypoxia-reoxygenation induced decrease in 
cardiac contractile force and contraction rate, and morphological alterations. The results 
demonstrate that catalase overexpression in the heart provides protection against cardiac 
oxidative damages.
xiv
CHAPTER I
INTRODUCTION
Adriamycin-induced cardiotoxicity is a major limiting factor for clinical 
application of this agent. A proposed mechanism for the cytotoxic effect of Adriamycin 
is the production of reactive oxygen species during its intracellular metabolism.
Although a number of studies have suggested that a relative lack of antioxidant defense, 
in particular low catalase activity in the heart, may be involved in the development of 
cardiotoxicity of Adriamycin, current approaches have not been able to provide complete 
understanding the relationship between low antioxidant capacity in the heart and 
Adriamycin cardiotoxicity. This chapter focuses on the relevant literature pertaining to 
Adriamycin and its cardiotoxicity, catalase and its physiological function, and the role of 
catalase in cardioprotection against oxidative damage.
Adriamycin (Doxorubicin)
Structure. Action, and Toxicity
In 1969, the anthracycline antibiotic Adriamycin was originally isolated from the 
fungus streptomyces pencetius (1). The anthracycline antibiotic has a tetracycline ring 
structure with an unusual sugar, daunosamine, attached by glycoside linkage (Fig. 1).
The quinone and hydroquinone moieties on adjacent rings function as electron-accepting
1
2Fig. 1. The chemical structure of Adriamycin. Chemically, Adriamycin consists of a 
water-insoluble tetracycline aglycone (structure A B C D) and a water-soluble reducing 
daunosamine sugar. Several parts of the molecule can be involved in the metabolism of 
Adriamycin. Ring C is a quinone group which can be activated into a semiquinone 
radical after one-electron reduction. Ring B is a hydroquinone which can also be 
activated into a semiquinone radical after one-electron-oxidation. The C9 side chain is 
probably important in the iron-catalyzed autoxidation of the molecule. Difference in the 
C9 side chain form the only difference between Adriamycin and its analog daunorubicin.
3z
4and -donating agents and can be activated into a semiquinone radical which is associated 
with the cytotoxicity of the drug.
Since the formulated compound was first made available for clinical use in the 
early 1970's, more than two million patients have received this medication. Adriamycin 
is presently a well established drug and a major therapeutic agent in the treatment of 
cancer. It is used extensively as part of combination chemotherapy regimens for the 
effective treatment of acute non-lymphocytic leukemia, Hodgkin’s and non-Hodgkin’s 
lymphomas, breast cancer and sarcomas (2,3). It has exhibited clinical utility in the 
treatment of human solid tumors including those of breast, lung, ovary, head and neck, 
endometrium, prostate, and bladder. It is also active against neuroblastoma, 
osteosarcoma, Ewing’s tumor, and rhabdomyosarcoma.
The acute toxic effects of Adriamycin may not relate to dose, but the chronic toxic 
effects of Adriamycin are dose related. Nausea and vomiting occur in more than 50% of 
patients receiving Adriamycin while some degree of alopecia is seen in all patients (5). 
Somnolence may occur during the first 24 hr after injection, and lethargy lasting for 
several days is often seen in the elderly. The dose-limiting toxicities of the anthracycline 
antibiotic are myelosuppression, mucositis, and cardiomyopathy.
Mechanism of Action and Toxicity
The mechanism of the antitumor activity of Adriamycin is not completely 
understood. A number of mechanisms have been proposed including intercalation of the 
anthracycline aglycone moiety between adjacent base pairs in the DNA double helix 
producing inhibition of DNA, RNA, and protein synthesis (4,5), inhibition of proteins
5associated with DNA strand breaks due to anthracycline-induced stabilization of the 
topoisomerase II-DNA complex with the DNA in the open conformation (6,7), and 
alteration of cell membrane function (8-10). Another mechanism for the cytotoxicity of 
Adriamycin is anthracycline free radical mediated alkylation and DNA degradation (11- 
13). However, none of these mechanisms alone appears adequate to explain all of the 
cytotoxic properties of Adriamycin (14,15). It is probable that the mechanism of 
antitumor activity of Adriamycin differs from that by which cardiac toxicity occurs, since 
a number of animal and clinical studies have shown that by altering the schedule of 
administration or by using protective agents it is possible to decrease the cardiotoxicity 
without reducing the antitumor effects of Adriamycin (16-19). Nausea and vomiting due 
to Adriamycin can be reduced by decreasing the peak plasma concentration of the drug 
(20). Myelosuppression, mucositis and alopecia appear from clinical studies to share a 
similar mechanisms of action to antitumor activity.
Cardiotoxicity
Cardiotoxicity is the most prominent adverse effect of Adriamycin. Acute 
cardiovascular effects of Adriamycin can develop within minutes but usually within a few 
hours of Adriamycin administration. Electrocardiographic studies show an incidence of 
abnormalities in up to 41% of patients receiving Adriamycin (21-24). The ECG effects 
include nonspecific S-T wave changes, sinus tachycardia, premature ventricular and atrial 
contractions, and low voltage of the QRS complex. These ECG changes are reversible in 
a few days to two months and do not appear to be associated with the development of 
Adriamycin cardiomyopathy. A change in myocyte morphology has been consistently
6observed. This change occurs within 10 min after administration of a single large dose of 
Adriamycin and returns to normal within 14 hours (25). These acute toxic effects are not 
dose-dependent and do not contraindicate further therapeutic application of the drug (26).
In contrast to the acute toxic effects, chronic cardiomyopathy induced by 
Adriamycin is the major drawback of the drug in cancer chemotherapy. Congestive 
cardiomyopathy is the cumulative dose-related toxicity of Adriamycin therapy and is 
proportional to the dose of Adriamycin administered (27,28). A total dose of 500-555 
mg/m2 has been shown in patients with no underlying cardiac disease and a total dose of 
450 mg/m2 has been recommended in patients receiving combined methods of therapy. 
Individual patients may tolerate higher total Adriamycin doses than the recommended 
maximum but the risk is considerable. The clinical presentation of patients with 
Adriamycin induced cardiomyopathy is non-specific. The first sign may be tachycardia 
with the patient complaining of shortness of breath or a nonproductive cough, and the 
usual signs of congestive failure include distended neck veins, gallop rhythm, ankle 
edema, hepatomegaly, cardiomegaly, and pleural effusion (29-31). The onset of 
symptoms generally occurs about one month after the first dose of Adriamycin but can 
vary from hours to as long as eight months (32). The primary cardiac morphologic 
changes observed in patients include loss of myofribris, cytoplasmic vacuolization due to 
swelling of the sarcotubular system, swollen mitochondria, enlarged nuclei with a large 
distinct nucleolus, increased numbers of lysosomes, and lipid accumulation (33-36). 
Percutaneous endomyocardial biopsies in patients have demonstrated a direct relationship 
between the total dose of Adriamycin and pathologic changes in the myocardium (37-39).
7Similar structural changes of Adriamycin cardiomyopathy have been seen in a variety of 
experimental animals (40-42). Although these morphological and functional descriptions 
of Adriamycin’s cardiotoxicity have been known for several years, the mechanism of 
production of these lesions and the reason for the selective toxicity to the heart remain 
unknown.
Free Radical Formation and Adriamycin Cardiotoxicity 
Free Radical Formation bv Adriamycin
Free radicals are chemical species that contain an electron with unpaired spin. 
This electronic phenomenon makes many free radicals very unstable and short-lived and 
capable of non-enzymatic oxidation of macromolecules including enzymes and other 
membrane and cytosol components (43,44). Biologically, unrestrained free radical 
production can lead to cell damage and death.
Hando and Sato first showed that the metabolism of Adriamycin and other 
quinone-containing compound could lead to free radical generation in a microsomal 
NADPFI-oxidase system (45). They found that reactive semiquinone free radicals were 
formed and reacted with molecular oxygen to produce the reactive superoxide anion (0 2‘ 
•). Two years later, Goodman and Hochstein showed that NADPH and purified 
cytochrome P450 reductase in the presence of Adriamycin consumed more oxygen from 
the media than predicted from the amount of drug presented (46). They postulated a 
reduction-autoxidation cycle for Adriamycin. In this way one molecule of Adriamycin 
could form many molecules of oxygen centered free radicals by cycling from a quinone 
to semiquinone then back to quinone following the reduction of molecular oxygen to
8superoxide anion. The superoxide anion generated by redox cycling of Adriamycin may 
initiate lipid peroxidation or be dismutated via superoxide dismutase to hydrogen 
peroxide. Free radicals, hydrogen peroxide and superoxide anion can damage membranes 
and macromolecules and cause cell damage. Hydrogen peroxide gives rise, by an iron 
catalyzed reaction to hydroxyl radicals that may react with: (a) unsaturated lipids causing 
lipid peroxidation and destruction (47,48); (b) cellular DNA, thereby inducing DNA 
damages (49-51); or (c) deoxyribose causing deoxyribose breakdown and degradation 
(52,53). Hydroxyl radicals can also be formed by the reaction of Adriamycin 
semiquinone radical with hydrogen peroxide (54,55). But the reaction of Adriamycin 
semiquinone radical with hydrogen peroxide can not effectively compete with the 
reaction of oxygen with Adriamycin semiquinone radical to form superoxide anion 
radical. A summary of the pathways for formation of oxygen radicals by redox 
cycling of Adriamycin is shown in Fig. 2.
Free Radical Chemistry of Adriamycin in Cardiac Tissue
Free radical production in cardiac cells due to one-electron-reduction of 
Adriamycin might occur at the nuclear envelope, in mitochondria, cytosol, or 
sarcoplasmic reticulum (56,57). The major site of Adriamycin-induced oxygen radical 
formation in the heart is complex I of the mitochondrial electron transport chain, probably 
the NADPH dehydrogenase (58,59). Heart muscle cells are extremely rich in 
mitochondria, which might render them particularly vulnerable to free radicals generated 
at these organelles. The major oxygen species formed by redox cycling of Adriamycin in 
the heart is hydroxyl radical (60). Using ESR and spin trapping with DMPO, Thomalley
9Fig. 2. Formation of oxygen radicals by redox cycling of Adriamycin. Adriamycin can 
be reduced by cellular flavoproteins to form its one-electron reduced semiquinone form. 
In the presence of oxygen the semiquinone free radical is oxidized back into the parental 
quinone form under formation of superoxide radicals. In the absence of oxygen the 
semiquinone is unstable, it loses its sugar moiety and an intermediate C7 free radical can 
be formed. This radical can bind covalently to cellular macromolecules
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and Dodd found only hydroxyl radical and no superoxide anion radical formed in rat 
heart sarcosomas incubated with NADPH and Adriamycin (61). Hydroxyl radical 
formation was inhibited by catalase but not by superoxide dismutase, suggesting a direct 
reduction of hydrogen peroxide to hydroxyl radical. Nohl and Jordan also found no ESR 
evidence for formation of superoxide anion radical by respiring rat heart mitochondria 
and Adriamycin using DMPO as a spin trap (62). In this study, an Adriamycin-derived 
semiquinone radical signal was seen which was stable even in the presence of oxygen. 
The signal disappeared on addition of hydrogen peroxide and concomitantly there 
appeared a DMPO-hydroxyl radical adduct signal. These results have been interpreted to 
indicate that an Adriamycin semiquinone radical was produced during mitochondrial 
respiration, probably at the lipophilic phase of the mitochondrial inner membrane, in a 
way which precluded electron transfer to oxygen. This allowed reaction at the 
anthracycline semiquinone radical with hydrogen peroxide, probably present at relatively 
high concentrations in the heart because of low levels of catalase, to form hydroxyl 
radical (63).
Free Radical- Induced Cardiac Dysfunction
Calcium released from sarcoplasmic reticulum (SR) appears to be involved in 
redox cycling of sulfhydryl groups of terminal cistemae . Peroxides and oxidizing agents 
promote rapid release of calcium from SR. Calcium sequestration was inhibited by 70% 
in rat cardiac SR preincubated for 30 min with Adriamycin (64,65). This inhibition was 
attenuated by incubation with catalase and the free radical scavengers, N-acetylcysteine 
and glutathione (66). Thus, free radicals may promote extensive calcium release and
12
depletion of SR calcium stores, leading to impaired contractility and impaired cardiac 
relaxation. Free radical-induced cardiac dysfunction may also reflect mitochondrial 
injury. Substantial amounts of superoxide anion are formed when Adriamycin and 
NADH are added to the mitochondrial fraction of rat heart (57). Lipid peroxidation is 
another mechanism that leads to oxidative damage. The reactive oxygen species may 
react with cellular molecules such as lipids to generate lipid peroxidation in the plasma 
membrane and cause lethal membrane damage.
Free Radical Mechanism of Adriamvcin-induced Cardiotoxicitv
The cardiotoxicity of Adriamycin has frequently been linked to the formation of 
reactive oxygen species (47,58,67-68). Support for the concept that Adriamycin produces 
its cardiotoxicity through an oxidative mechanism comes from several laboratories.
Olson et al. showed that although Adriamycin lowers glutathione (GSH) levels in heart, 
liver, and red blood cells of mice, the lowest value in liver was still eight times greater 
than the corresponding value for GSH in the heart. Olson further showed that if cardiac 
GSH was depleted by diethyl maleate prior to Adriamycin administration, significant 
potentiation of acute Adriamycin-induced lethality occurred. Conversely, the acute 
lethality and cardiac lesions produced by Adriamycin could be prevented by prior 
administration of sulfhydryl donors that also prevented the Adriamycin-induced fall in 
myocardial GSH concentrations (69,70). Another study showed that mice pretreated with 
N-acetylcysteine survived for a significantly longer time than those receiving Adriamycin 
alone and that pretreatment with N-acetylcysteine prevented the ultrastructural cardiac 
lesions associated with acute Adriamycin administration (71). Sulfhydryl donors such as
13
cysteamine and N-acetylcysteine are very reactive toward free radicals through non- 
enzymatic donation of hydrogen atoms (72). Thus, exogenously administered sulfhydryl 
donors are preferentially oxidized by oxygen centered free radicals, thereby protecting the 
tissue from oxidative damage. Another study showed that when mice were placed on a 
selenium-free diet to reduce endogenous glutathione peroxidase activity (selenium being 
a required cofactor for glutathione peroxidase), the mortality produced by acute 
Adriamycin administration doubled (73). Myers et al. found that the antioxidant vitamin 
E significantly protected mice from acute Adriamycin-induced cardiotoxicity (74). These 
studies suggest that Adriamycin produces toxicity through an oxidation mechanism.
Further evidence that links Adriamycin-cardiotoxicity to oxygen radical formation 
is the finding that newer, less cardiotoxic anthracyclines undergo less redox cycling than 
Adriamycin. Studies by Lown et al. have shown a positive correlation between the 
electrochemical generation of oxygen species from a series of anthracyclines and their 
cardiotoxicity in the rat. 5-Iminodaunorubicin which is less cardiotoxic in animals than 
either daunorubicin or Adriamycin does not undergo enzymatic reduction to form an 
anthracycline semiquinone radical (60,68,75-77). 4'-Deoxydoxorubicin and 4- 
demethoxydaunorubicin, which in experimental animals are less cardiotoxic than 
doxorubicin or daunorubicin, do not generate oxygen free radicals spontaneously in 
aerated aqueous solution, unlike the parent anthracycline (78,79). Both compounds are, 
however, equally active as doxorubicin in stimulating oxygen use when incubated with
rat liver microsomes and NADPH.
14
Lipid peroxidation is an important indicator of oxidative damage. Unsaturated 
fatty acids are peroxidized when exposed to hydroxyl radicals in the presence of a metal 
catalyst (80). This process might damage cellular membranes and eventually kill cells. A 
number of studies indicated that Adriamycin increased lipid peroxidation in intact cardiac 
tissues and organelle preparation (47,81-83). In the presence of oxygen, Adriamycin- 
dependent lipid peroxidation is generally inhibited by superoxide dismutase, catalase, 
glutathione, iron chelators, and hydroxyl radical scavengers (82-84). Studies with rat 
heart microsomes and NADPH have shown that Adriamycin stimulates lipid 
peroxidation, but only if the microsomes are prepared from rats fed a diet deficient in a- 
tocopherol (85,86). Mouse heart microsomes, which have low endogenous levels of a- 
tocopherol, exhibit a marked increase in lipid peroxidation in the presence of Adriamycin 
(66,84). 4'-Epidoxorubicin, which is less cardiotoxic than Adriamycin in mice, does not 
increase lipid peroxidation measured by malondialdehyde formation in mouse heart in 
vivo (87). Studies using breath ethane expiration, which is generally considered as a 
more reliable indicator of lipid peroxidation in vivo, have failed to show an increase in 
lipid peroxidation in rats given lethal doses of Adriamycin (88). However, several 
compounds that are believed to exert their toxic effects through generation of active 
oxygen species and lipid peroxidation, for example nitrofurantoin, paraquat, diquat, and 
menadione, also did not increase ethane production in vivo in this system (89). Thus, the 
failure to demonstrate an Adriamycin-dependent increase in ethane production in intact 
animals can not be taken as conclusive evidence for a lack of lipid peroxidation in the
heart in vivo.
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In summary, the available data suggest that Adriamycin produces its 
cardiotoxicity through an oxidative free radical mechanism. However, the free radical 
hypothesis has serious limitations. For example, at cardiotoxic concentration Adriamycin 
often fail to generate free radicals or produce evidence of oxidative stress (90-92). In 
addition, free radical scavengers often fail to prevent Adriamycin cardiotoxicity (93-95). 
Therefore, the free radical mechanism of Adriamycin-induced cardiotoxicity needs to be 
further studied.
Catalase
History and Structure of Catalase
Catalase is widely distributed in a variety of life forms and has been studied in 
great detail (96-99). In 1818 Thenard observed that hydrogen peroxide was decomposed 
by animal tissues with the liberation of gaseous oxygen: 2H20 2 -  2H20  + 0 2. Eighty- 
three year later, in 1901, Loew (100) demonstrated that this effect was due to a specific 
enzyme which he named catalase. In 1923, Warburg (100) suggested that catalase was an 
iron-containing enzyme because it was inhibited by cyanide. Evidence that its prosthetic 
group was hematin was provided by Zeile and Hellstrom in 1930 (100). The enzyme was 
first crystallized from beef liver by Summer and Dounce in 1937 (101). It has since been 
crystallized from liver and erythrocytes of a number of animal species, including the 
human (100). It has also been crystallized from bacteria (102). The primary structure of 
beef liver catalase has been established but the complete sequence of human catalase is 
not yet known. Chemical analyses have confirmed that the native enzyme has a 
molecular weight of 240,000 daltons, and possesses four subunits of the same size and
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amino acid sequence (103-105). Each subunit has an apparent molecular weight of about 
60,000 and contains one ferriprotoporphyrin (hematin) group. Genetic studies, utilizing 
the inborn error “acatalasemia” in humans and mice have indicated that a single 
structural gene is responsible for the total synthesis of the enzyme (106,107). Despite 
this single gene specification and identity of amino acid composition, a number of studies 
have provided evidence for the existence of multiple forms of catalase activity in 
mammalian organisms. The first electrophoretic separation was carried out by Holmes 
and Masters in 1965, and since then multiplicity has been reported by several other 
groups (108-110). The major causation of multiplicity in mammalian tissues may be 
related to the various possibilities of epigenetic modification, including oxidation of 
sulphydryl groups (97,111,112), proteolytic modification (113,114), and modification of 
carbohydrate moieties (115,116). Catalase heterogeneity provides a sensitive indication 
of the functional variations which occur within separate compartments of subcellular 
structure.
The Primary Function of Catalase
Catalase is generally regarded as the single component most closely synonymous 
with the peroxisome (98). Catalase is one of the most important intracellular enzymes in 
the detoxification of the oxidant hydrogen peroxide (117). Hydrogen peroxide is not only 
a normal by-product of cell respiration, being derived from the dismutation of superoxide 
by superoxide dismutase, but also arises from the oxidation of fatty acids and the 
metabolism of certain compounds (99). Although the enzymatic reaction of catalase has 
been intensively studied the exact mechanism of catalysis has not been established and its
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physiological role has remained perplexing (118-121). Catalase has a very high turnover 
number, decomposing the H20 2 into 0 2 and H20  at an exceedingly high rate (catalytic 
activity). This activity is not its only function. In the presence of very low 
concentrations of H20 2 (<10'6M), it will also oxidize electron donors such as ethanol or 
phenols (peroxidatic activity). Because catalase has two enzymatic functions and the fact 
that H20 2 production in different tissue can vary within a wide range, the actual function 
of catalase may vary from tissue to tissue or from one subcellular compartment to 
another. Catalase may react either catalytically or peroxidatically depending on the 
microenvironment of the cell. Also, the level of H20 2 is regulated physiologically at 
concentrations of 10'7 - 10'9M. At these H20 2 concentrations, another enzyme, 
glutathione peroxidase, is believed to decompose the H20 2 because it has a higher affinity 
for H20 2 than does catalase (119). It is currently believed that both catalase and 
glutathione peroxidase contribute to the breakdown of H20 2 in vivo and that both 
enzymes have important functions, their relative contribution being dictated by their 
subcellular distribution, their localized concentration, and the availability of H20 2, 
hydrogen donors, and reduced glutathione (123,124). Glutathione peroxidase is believed 
to be of major importance in the breakdown of H20 2. However, the relative contribution 
of catalase should increase with increasing concentration of H20 2 (124).
Hydrogen peroxide is a normal cellular metabolite as well as a potentially reactive 
form of oxygen which could cause oxidative damage to tissue. It readily permeates 
biological membranes and is believed to diffuse from one cell compartment to another, 
into interstitial fluid, and into the circulation. The intertissue and intracellular
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partitioning of catalase and glutathione peroxidase would appear to provide a dual and 
complimentary defense mechanism against this mobile source of oxidative stress.
Tissue Distribution and Subcellular Localization
Catalase is ubiquitously present in aerobic cells containing a cytochrome system. 
It is missing in most anaerobic organisms, but occurs in the radioresistant species, 
micrococcus radioresistants. These observations have cause speculation about its in vivo 
role (119,121,125). Catalase is most abundant in the liver and kidney, correlating with 
the cellular content of peroxisomes as identified by histochemical techniques (96,98,126). 
However, in some species, considerable catalase activities have also been found in the 
soluble cytosol of liver (96). A high level of enzyme activity of catalase is also found in 
erythrocytes, while lung and pancreas show intermediate values. Very low activities are 
found in the heart and brain (127).
Catalase is mainly localized in peroxisomes, but it has also been identified in the 
endoplasmic reticulum and cytoplasm (118,119,121). Although it was previously 
believed that catalase was present in mitochondria, this view has been questioned (123). 
Cytoplasmic catalase is associated with the cellular membrane and may well be involved 
in the protection of this structure from lipid peroxidation (128,129). In heart and smooth 
muscle, the small amount of catalase is confined to microperoxisomes, situated between 
adjacent myofibrils, and often closely related to mitochondria (130-133). In skeletal 
muscle, catalase seems to be associated with the sarcoplasmic reticulum (134). The 
highest catalase activity has been found in slow oxidative muscle. In a given muscle 
type, the catalase activity varies from one region to another (134,135). Catalase in the
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mature red blood cell has been regarded as cytoplasmic. However, several reports have 
provided evidence that catalase is associated with or present in the erythrocyte membrane 
(136-139). In liver cells, catalase is synthesized as a monomer in the endoplasmic 
reticulum and is rapidly transferred to the peroxisomes where final assembly to the 
tetramer takes place (140).
It seems to be impossible that a protein of the size of catalase (240,000 daltons) 
should be able to pass through the peroxisomal membrane. However, a number of studies 
have indicated that catalase is able to pass through the peroxisomal membrane into the 
cytoplasm under the appropriate physiological conditions (141).
Catalase and Disease
Xeroderma pigmentation (XP) is an autosomal recessive disease characterized by 
extreme sensitivity to sunlight and a high incidence of skin cancer. A decline in catalase 
activity has been found to coincide with the first symptom of the catalase and progression 
to tumor formation (142). The fibroblasts from patients with XP were found to have only 
25% of the expected catalase activity (143). These data suggested that the decrease in 
catalase activity permitted an increase in intracellular hydrogen peroxide which was 
postulated to be a factor in the eventual development of the malignant process.
The activity of the various intracellular antioxidants was measured in patients 
with either acute or chronic renal failure (144). The results suggested that renal failure 
induced some form of stress which produced lipid peroxidation and enhanced catalase
activity.
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Ischemia-reperfusion injury occurs when an organ or tissue which has been 
deprived of oxygen is reoxygenated. The injury has been associated with oxyradicals 
(145). In the isolated heart model, catalase added to the reperfusion solution effectively 
provided protection against ischemia-reperfusion injury (146). In another in vitro system 
using cultured pulmonary endothelial cells, the addition of catalase reduced the injury 
resulting from anoxia-reoxygenation (147).
In a variety of animal species, malignant tumors appear to have reduced catalase 
activity. A three-fold decrease in red blood cell catalase activity has been observed in 
mice with Ehrlich ascites tumors (148-151). Catalase in the liver was reduced by a tumor 
and restored when the tumor was removed (152). A possible mechanism is the 
observation that the cachexia and starvation accompanying cancer can cause a significant 
depression of catalase activity in many species. This and a number of other possible 
explanations have been reviewed by Kampschmidt (153).
Catalase and Cardiac Oxidative Damage 
Oxidants are ubiquitous in our aerobic environment and are formed in situ in 
tissue and cells by normal metabolism and the metabolism of certain xenobiotics. The 
rate of production of reactive oxygen species can be amplified by neutrophil activation, 
hyperoxia, metabolism of redox active drugs, radiation exposure, and ischemia 
(154,155). Reactive oxygen species, including superoxide, hydrogen peroxide, and 
hydroxyl radicals, have been implicated as causative agents in damage to DNA, proteins, 
and cell membranes (156-158 ) and involved in the development of various pathological 
states such as Adriamycin cardiotoxicity and ischemia-reperfusion injury (159).
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Tissues normally possess biological defense systems to protect against oxidative 
damage. Two basic free radical defense systems, primary and secondary, have been 
defined (160). The primary defense system consists of antioxidant enzymes, including 
superoxide dismutase, catalase, and glutathione peroxidase, and nonenzymatic 
components, including glutathione, metallothionein, a-tocopherol, and ascorbate. This 
system provides the first line of defense against free radicals. The secondary defense 
system includes enzymes and other mechanisms for repairing free radical-induced cell 
damage. These systems exist in almost all cell types (117). However, cellular responses 
to oxidative stress are different from one cell type to another, suggesting that alterations 
in antioxidant defense, such as differential distribution of the antioxidant enzymes, occur 
between cell types. Under normal conditions, a balance between free radical generation 
and free radical defense system exists (summary in Fig. 3). But, oxygen free radicals can 
initiate cellular damage if they overwhelm the antioxidant defense mechanisms.
Cardiac tissue appears to be particularly sensitive to free radical-induced toxicities 
(161,162). This is probably not only the result of the relative abundance of mitochondria 
and efficient hydroxyl radical formation, but also of a relatively poor antioxidant defense 
system (163, 164). Heart, compared to the liver, has a much weaker enzymatic defense 
system (165 ). It has been shown that catalase activity in the heart is about 2% of that in 
the liver of the mouse (161,163). Catalase, the major enzyme involved in detoxification 
of H20 2 in mammalian cells, is thought to be deficient in the heart due to it’s inability to 
dispose of reactive oxygen species. This may be responsible for the unusual sensitivity of 
the heart to oxidative damage.
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Fig. 3. Free radical generation and free radical defense systems. Free radicals are formed 
in tissue and cells by normal metabolism and the metabolism of certain xenobiotics. The 
generated superoxide is converted to hydrogen peroxide by superoxide dismutase (SOD). 
Hydrogen peroxide is further converted into water and oxygen by glutathione peroxidase 
(GSHpx) and catalase. In the normal condition, there is a balance between free radical
generation and free radical defense system.
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The Role of Catalase in Cardioprotection against Oxidative Damage
Several studies have been undertaken to determine the role of catalase in 
cardioprotection against oxidative damage. Isolated animal hearts were often used for 
such studies. It has been shown that addition of perfusion medium with catalase 
significantly reduces ischemia-reperfusion injury to the isolated rat heart by detoxifying 
H20 2 (165). The role of catalase in metabolism of H20 2 in the heart tissue was tested 
directly by adding H20 2 into perfusion medium (166). In that study, changes in GSSG 
concentration in the effluent perfusate were measured as an indicator in GSHpx 
metabolism of H20 2. Rats were treated with aminotriazole, an inhibitor of catalase, 
before the heart was isolated. This treatment inhibited cardiac catalase activity by 83%.
It was found that in the catalase-depressed heart 50 pM H20 2 caused GSSG efflux at the 
rate of 5 nmol/min per g heart, whereas 200 pM H20 2 was required to obtain a similar 
rate of GSSG release from the control heart. The result thus shows that catalase, although 
present at low levels of activity in the heart compared to other organs, functions in 
detoxification of H20 2 in the myocardium.
The cloning and nucleotide sequences of cDNAs for catalase have been reported 
for human and rodent tissues (167,168). Many studies were thus conducted using these 
cDNAs to increase cellular catalase activity to determine the physiological role of this 
enzyme. Transfection of acatalasemic murine fibroblasts with a eukaryotic expression 
vector harboring a human catalase cDNA clone produced stably transfected cell lines. 
These cells overexpressed catalase activity and exhibited a significant resistance to 
oxidative stress relative to the untransfected cells (169). Similar studies have been done
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using other cells. For example, transfection of human bronchial epithelial cells with a 
human catalase cDNA elevated their catalase activity and increased the survivability of 
the cells when exposed to hyperoxia (170). Human umbilical vein endothelial cells 
transfected with a human catalase cDNA also exhibited elevated catalase activity, closely 
correlated with increased catalase protein levels (171). When the endothelial cells were 
exposed to 500 pM H20 2, all the transfected cells survived, compared to only 37% of 
untransfected cells (171). A recent study has shown that simultaneous overexpression of 
superoxide dismutase (SOD) and catalase in Drosophila melanogaster extended their life­
span by as much as one-third (172). Furthermore, infection with HIV reduced levels of 
catalase activity in T cells and enhanced their susceptibility to killing by H20 2.
However, contradictory results were also reported. Transfection of L cells with a 
human catalase cDNA elevated catalase activity by 100-fold. These catalase-enriched 
cells, however, were more sensitive rather than resistant to the cytoxicity of paraquat, 
bleomycin, and Adriamycin than the untransfected cells from which they were derived 
(173). The increased sensitivity of the transfected cells to these agents which reduce 
dioxygen was in part attributed to the catalase-generated 0 2. It has been interpreted that 
by capturing H20 2 and converting it to 0 2, catalase can maintain the concentration of 0 2 
either for repeated rounds of chemical reduction or for direct interaction with the drugs. 
Several other studies have raised an issue regarding the balance between SOD and 
catalase. Transfection of mouse epidermal JB6 cells with a human SOD cDNA increased 
the enzyme activity and rendered the cells hypersensitive to the cytotoxicity of 
superoxide plus H20 2 (174). Although elevation of catalase alone by transfection with
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human catalase cDNA protected the cells from oxidant damage, simultaneous elevation 
of the two enzyme activities by transfection provided much greater protection (175). In 
the Drosophila study, it was also found that overexpression of SOD alone or catalase 
alone had only a minor incremental effect on the average life-span (176,177). These 
studies demonstrate the importance of an optimum balance between SOD and catalase.
Statement of Problems
As stated above, the relative deficit in cardiac catalase activity may be an 
important factor responsible for the unusual sensitivity of the heart to oxidative damage. 
This hypothesis has been continually tested using isolated hearts and other in vitro 
models. A major limitation of currently existing approaches is that the isolated heart 
perfused with catalase serves as a model for studying only acute toxicity. In cancer 
chemotherapy, chronic rather than acute drug toxicity is a major problem. Thus, a stable, 
chronic rather than short-term approach is more appropriate for these studies. In addition, 
transfection of cultured cells with catalase cDNA provides only in vitro understanding of 
the role of catalase in detoxification of reactive free radicals. Contradictory conclusions 
may result from this limitation. For example, in culture, the 0 2 generated from H20 2 by 
catalase may be responsible for the increased sensitivity of the catalase-enriched L cells 
to oxidant toxicity (174). This may not be the same case in vivo because of the more 
complicated regulation of 0 2 sense and transport systems. Therefore an unique in vivo 
model is clearly required to overcome these limitations and to precisely determine the 
role of catalase in protection against Adriamycin cardiotoxicity.
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Significance of the research
Heart damage is a severe toxic effect of Adriamycin, resulting in the limitation of 
its application in cancer chemotherapy. Therefore an understanding of the mechanism for 
the unusual sensitivity of the heart to Adriamycin toxicity is necessary for the 
development of experimental and clinical approaches to improved use of Adriamycin in 
cancer chemotherapy. A possible mechanism for Adriamycin cardiotoxicity is the 
production of oxygen free radicals during its intracellular metabolism. The heart with a 
weak antioxidant system, in particular low catalase activity, may be responsible for the 
unusual susceptibility of the heart to Adriamycin toxicity. Therefore, we decided to 
develop a transgenic mouse model in which catalase is constitutively overexpressed 
specifically in the heart tissue. This unique model would thus provide an unequivocal 
approach to understanding the role of catalase in cardiac protection against Adriamycin 
toxicity as well as other cardiac injury, such as ischemia-reperfusion damage and many
other oxidative deteriorations.
CHAPTER II
MATERIALS AND METHODS
Construction of the transgene for overexpressing catalase specifically in the heart 
A transgene, designated MyCat, was constructed for over expression of catalase in 
cardiac tissue of transgenic mice (summary in Fig. 4). The procedures for plasmid 
construction and DNA preparation were as described by Maniatis (178). All plasmids 
were grown in the DH5a ™competent cells. The plasmid Clone 20 (179), pRCA38 (180) 
and pRip-InsII (181) were used. The plasmid pRCA38 (provided by Dr. Shuichi Furuta, 
Shishu University School of Medicine, Japan), containing the complete coding region of 
rat catalase cDNA, was digested with Nco I followed by treatment with the Klenow 
fragment of DNA polymerase to fill the single-stranded end. It was then digested with 
Hind III and extracted with phenol/chloroform. The plasmid Clone 20 ( provided by Dr. 
Jeffrey Robbins, University of Cincinnati College of Medicine), containing the alpha 
cardiac myosin heavy chain (MHC) promoter, was digested by Sal I, filled in with 
Klenow and digested with Hind III. The plasmid DNAs were then ligated to produce the 
MyCat I plasmid where the rat catalase cDNA is under the regulation of the MHC 
promoter. A 600-bp Xhol blunt-Hind III genomic fragment of the plasmid pRip-Ins II 
(provided by Dr. Paul Epstein, University of North Dakota School of Medicine) was
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Fig. 4. Construction of MyCat transgene, the plasmids Clone 20 and pRCA 38 were 
digested with sal I and Nco I respectively. The gaps were filled with klenow and both 
plasmids digested with Hind III and ligated to produce the MyCat I plasmid. A 600-bp 
fragment of Xho I and Hind III digested Rip-Int II gene and BamH I / Hind III fragement 
of MyCat I were ligated to yield MyCat II. Then MyCat II plasmid was digested by Sma 
I and Hind III and ligated together to generate MyCat III plasmid.
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inserted behind the catalase cDNA in BamHI blunt-Hind III sites of the MyCat I plasmid 
to provide polyadenylation site and termination signals, producing the MyCat II plasmid. 
For modification of MyCat II, a 1400-bp fragment containing two introns and one exon 
of the Insulin gene were moved from the MyCat II by Sma I/Hind III digestion, then 
ligated together to yield MyCat III plasmid. For production of transgenic mice, plasmid 
sequences were removed from the MyCat III by Notl digestion and an 8-kb MyCat 
transgene (shown in Fig.5) was generated.
Production of transgenic mice
Transgenic mice were generated by microinjection of the transgene into single­
cell embryos by standard techniques (182 ). Prior to injection, the transgene was purified 
by Nal-glass bead extraction (geneclean, BIO 101) and filtered through 0.22 pm filters. 
The DNA sample for microinjection was free of contaminants that might harm the eggs, 
such as traces of phenol, ethanol, or enzymes. In addition, it was essential to get rid of 
any particulate matter that might clog the injection needles. Embryos were isolated from 
superovulation 4- to 6 week old FVB females that were treated by pregnant mare's serum 
(PMS) and human chorionic gonadotropin (hCG). On average, 20-30 eggs were 
recovered from the superovulated female. Microinjections of purified DNA at 2 pg/ml 
in 10 mM Tris-HCl / 0.1 mM EDTA, pH 7.6, were inserted into one pronucleus for each 
embryo, 12-14h after fertilization. Embryos that survived microinjection were implanted 
into pseudopregnant females and allowed to develop to term. Founder mice were crossed 
with FVB mates and transgenic lines were maintained in the FVB strains. A summary of 
the procedure is given in Fig.6.
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Fig. 5. Structure of the 8-kb MyCat transgene insert. The hatched and open boxes 
indicate the promoter and first three noncoding exons of the alpha cardiac MHC 
gene, respectively. The black box indicates the catalase cDNA and the slashed box 
indicates 3' genomic sequences of the rat insulin II gene. Arrow 1 shows the 
transcription initiation site, arrows 2 and 3 show the catalase start and stop codon, 
respectively. Arrow 4 shows the polyadenylation sequence from the rat insulin II 
gene.
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Fig. 6. Embryos were isolated from superovulation 4- to 6 week old FVB females that 
were treated by PMS and hCG. On average, 20-30 eggs were recovered from the 
superovulated female. The purified DNA at 2 |ig/ml in 10 mM Tris-HCl / 0.1 mM 
EDTA, pH 7.6, was microinjected into one pronucleus for each embryo, 12-14h after 
fertilization. Embryos that survived microinjection were implanted into pseudopregnant 
females and allowed to develop to term. Transgenic founders were identified by 
Southern blot, Dot blot and PCR analysis.
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Molecular Analyses 
Southern blot
Genomic DNA was isolated from tails clipped from 20- to 30- day - old mice 
under anesthesia by using a QiaAmp kit (Qiagen Inc. Chatsworth, CA). Five pg of tail 
DNA was digested with EcoRI and then extracted with phenol/CHCl3. The DNA was 
separated by agarose gel electrophoresis and was then depurinated in 0.25 N HC1. After 
denatured in 0.4 N NaOH, DNA was transferred to a nylon membrane in an alkaline 
solution of 0.4 N NaOH. The membrane was incubated with church buffer consisting of 
0.5 M Na2HP04, 1% BSA, and 0.7% SDS, pH 7.0 and 0.1 mg/ml of heat-denatured tRNA 
and salmon sperm DNA at 65°C for a period of 3 hr and then hybridized with a 32P- 
labeled probe in church buffer. After hybridization, the membrane was washed twice 
with wash buffer A (1% BSA, 5% SDS, 0.04 M PB, 1 mM EDTA) and four times with 
wash buffer B (1% BSA, 0.04 M PB, and 1 mM EDTA) and exposed to X-ray film at - 
80°C. The probe used was a 550-bp Smal and Notl fragment of the MyCat transgene. If 
the chimeric transgene was present in the genome, EcoRI digestion would result in a 
fragment that would specifically hybridize with the probe.
Ppt blpt
One pg genomic DNA was digested with restriction endonuclease EcoRI and was 
denatured in 200 pi of 0.25 N NaOH, and 0.5 N NaCl for 10 min. The reaction mixture 
was then loaded in wells of the Bio-Rad apparatus. After 30 min, the sample was sucked 
through the membrane. The membrane was then washed in 0.5 M NaCl, 0.5M Tris pH
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7.5 for 1 min and baked at 80 °C for 30 min. The hybridization procedure was the same 
as the Southern blot.
Polymerase chain reaction ('PCRO
The PCR method was used to identify transgenic mice. The oligonucleotide 
primers of 20-mer for the PCR analysis was obtained from DNA International. The 5' 
primer derives from the MHC promoter sequence and the 3' covers the catalase codon. 
The primer sequences are: 5' “AGG CTA CGG TGT AAA AGA GG ” and 3' “ GTG 
GGT GAC CTC AAA GTA TC ”. This design ensures the 450-bp PCR product will not 
obtain from the normal mouse DNA. The PCR conditions are as follows: to a sterile 
0.5-ml tube was added 10 y 1 of 5X F buffer (10 mM potassium chloride, 300 mM Tris 
hydrochloride, pH 9.0 and 75 mM ammonium sulfate ), 5 y\ of a 10 mM aqueous 
deoxynucleotide triphosphate solution, 0.2 yl Taq polymerase, 0.5 y\ each of the 5' and 
the 3' primers (2.5 yg/yi), 1 yl NAT oligo (2.5 yg/yl), 5 yl of the DNA solution from the 
mouse tail digestion, and water to make a total volume of 50 yl. The PTC-100 
Programmable Thermal Controller with the Hot Bonnet/60 was purchased from MJ 
Research, Inc. The PCR cycles are 1 min at 94°C, 2 min at 55°C, and 3 min at 72°C. 
After completion of 34 PCR cycles, the mixture was incubated for 7 min at 72°C. The 
PCR products were stored at -20°C. To analyze the PCR products, 25 yl of the mixture 
was subjected to 1% agarose gel electrophoresis.
Northern blot analysis
Total RNA was extracted from the myocardium tissue using the RNAzol B 
method (Cinna/Biotex). RNA was quantified spectrophotometrically and confirmed by
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ethidium bromide staining of 18S and 28S ribosomal RNA. RNA was then denatured in 
formaldehyde, fractionated on 1.1% agarose gels and transferred to nylon membranes.
The probe corresponding to a 900-bp Hind III and Bgl II fragment of the rat catalase 
cDNA was randomly labeled with [a-32P]dCTP (DuPont/NEN Research Products,
Boston, MA) using the Klenow fragment of DNA polymerase I (Bethesda Research 
Laboratories, Gaithersburg, MD) and purified by chromatography (Sephadex G-50, 
Sigma) before hybridization. Hybridization and wash procedures were conducted using 
previously published methods. After autoradiography, the membrane was stripped and 
rehybridized with human beta-actin cDNA probe to ensure the integrity of the RNA 
sample and to confirm that equal amounts of RNA had been loaded onto all lanes. 
Autoradiographic images were scanned and analyzed using the MCID system from 
Imaging Research Inc. (Ontario, Canada), which is available within our department.
Biochemical analyses 
Catalase
The method for determination of catalase activity described by Aebi [183] was 
followed with some modification. Catalase exerts decompose H20 2 to give H20  and 0 2. 
The decomposition of H20 2 can be followed directly by the decrease in absorbance at 240 
nm. Therefore, the difference in absorbance ( A240) per unit time is a measure of the 
catalase activity. To avoid inactivation of the enzyme during the assay or formation of 
bubbles in the cuvette due to the liberation of 0 2, it is necessary to use a relatively low 
H20 2 concentration (10 mM, final reaction concentration). Tissue samples were placed in 
liquid nitrogen and then at -80° C for less than 36 hr. Myocardial tissue was
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homogenized in 10 volumes of 1.0% triton X-100 using a variable speed tissue tearer 
(Biospe, Products, Inc.). The homogenate was then centrifuged at 10,000 rpm at 4° C for 
20 min to remove nuclei and cell debris. The supernatant was diluted with the assay 
buffer, 50 mM KH2PO4/50 mM Na2HP04 (1:1.5, pH 7.0), to avoid the UV absorption of 
Triton X-100. Catalase activity was measured by spectrophotometeric analysis at 240 
nm. Two ml of the sample was apaced in a cuvette. The reaction was initiated by 
adding 1 ml 30 mM H20 2, and the decrease in absorbance at 240 nm was monitored at 
25° C for 1.0 min. A portion of the remaining sample was used for protein 
determination. Specific activity was expressed as pmol H20 2/min per milligram of 
protein.
Superoxide dismutase (SODl
Myocardial tissue was washed with saline to remove excess connective tissu and 
red blood cells. The tissue was then minced in 3 vol of 0.05 M phosphate buffer, pH 7.8, 
using scissors. The minced tissue was homogenized with a Tekmar SDT ultraspeed 
tissue grinder (6 x 5-s bursts). The homogenized samples were centrifuged at 20,000g for 
60 min and the supernatant was assayed. All procedures were performed on ice. The 
method used for the assay of SOD activity is a modification of an indirect inhibition 
assay developed by Beauchamp and Fridovich [184]. Xanthine-xanthine oxidase was 
utilized to generate a superoxide flux. Nitroblue tetrazolium (NBT) reduction by 0 2' to 
blue formazan was followed at 560 nm with a Beckman model DU-65 spectrophotometer 
at room temperature. The rate of NBT reduction in the absence of tissue was used as the 
reference rate. When increasing amounts of the homogenized supernatant (containing
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SOD activity) were added to the system, the rate of NBT reduction was progressively 
inhibited. The amount of inhibition is defined as a percentage of the reference rate of 
NBT reduction when SOD activity is not present. The data were plotted as percentage 
inhibition vs protein concentration. One unit of activity is defined as the amount of 
protein necessary to decrease the reference rate to 50% of maximum inhibition. The 
assay mixture also contains catalase to remove H20 2 and DETAP AC to chelate metal ions 
capable of redox cycling and interfering with the assay system. NaCN (5 mM) was added 
(for 45-50 min) to assay MnSOD activity, if required. The MnSOD activity was 
subtracted from the total SOD activity to calculate the CuZnSOD activity. Each 1-ml 
assay tube contained final concentrations of the following reagents: 50 mM potassium 
phosphate buffer, pH 7.8; 1 mM DETAP AC; 1 unit catalase; 5.6 x 10'5M NBT; 0.1 mM 
xanthine; enough xanthine oxidase to achieve the required reference rate; and sample 
ranging from 0 to 500 \j .g of tissue protein. Protein content was measured using the 
Pierce BCA protein assay reagents as previously described [185].
Glutathione peroxidase IGSHpxl
This enzyme activity was measured using the method described by Flohe and 
Gunzler [186]. The homogenized tissue sample in 0.1 M potassium phosphate buffer 
containing 1.0 mM EDTA, pH 7.0, was centrifuged at 20,000g for 60 min. The 
supernatant fraction was used for the assay of GSHpx. The assay is based on GSSG 
formation during the GSHpx reaction. GSSG is instantly formed and continuously 
reduced by an excess of glutathione reductase (GR), providing for a constant level of 
GSH. NADPH is the co-factor required by GR. Therefore, the GSHpx activity is
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measured by photometrically monitoring the concomitant oxidation of NADPH. The 
reaction mixture contains 0.5 ml phosphate buffer (pH 7.0), 0.1 ml sample, 0.1 ml GR 
(0.24 U), and 0.1 ml of 10 mM GSH. The mixture was preincubated for 10 min at 37°C. 
Following incubation, 0.1 ml 1.5 mM NADPH in 0.1% NaHC03 was added to the 
mixture, and the hydroperoxide-independent consumption of NADPH was monitored for 
3 min. The overall reaction was started by adding 0.1 mM of prewarmed hydrogen 
peroxide (1.5 mM). The decrease in absorbance at 340 nm was monitored with a 
Beckman DU-65 spectrophotometer. The nonenzymatic reaction rate was 
correspondingly assessed by replacing the sample with buffer. One unit of the enzyme is 
defined as the amount of enzyme that catalyzes the oxidation of one pmole of NADPH 
per min monitored at 340 nm.
Glutathione Reductase IGRl
This enzyme activity was measured using the method described by Carlberg and 
Mannervik [187]. The homogenized tissue sample in 0.2 M potassium phosphate buffer 
containing 2.0 mM EDTA, pH 7.0, was centrifuged at 10,000 rpm for 60 min. The 
supernatant was used for the assay of GR. The assay is based on reduction of glutathione 
disulfide (GSSG) to glutathione by glutathione reductase. NADPH is the co-factor 
required by GR. Therefore, the GR activity was measured by photometrically monitoring 
the concomitant oxidation of NADPH. To a 1-ml cuvette, 0.5 ml of 0.2 M phosphate 
buffer (pH 7.0), 0.1 ml of 2 mM NADPH in 10 mM tris-HCl (pH 7.0), 0.1 ml of 20 mM 
GSSG, and 0.2 ml deionized water were added. The reaction was initiated by the 
addition of enzyme to the cuvette and the decrease in absorbance at 340 nm was followed
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at 30 °C. A unit of glutathione reductase activity is defined as the amount of enzyme that 
catalyzes the reduction of 1 )imol of NADPH per minute. Specific activity is expressed 
in units per milligram of protein.
Glutathione (GSH and GSSG)
The DTNB-glutathione reductase recycling assay first reported by Owens and 
Belcher (188) and later modified by Tietze (189) was used to measure glutathione. The 
recycling assay for total GSH (GSH + GSSG, in GSH equivalents) is a sensitive and 
specific enzymatic procedure. In this reaction, GSH is oxidized by 5,5'-dithiobis (2- 
nitrobenzoic acid) (DTNB) to give GSSG with stoichiometric formation of 5-thio-2- 
nitrobenzoic acid (TNB). GSSG is reduced to GSH by the action of the highly specific 
glutathione reductase (GSSG reductase) and NADPH. The rate of TNB formation is 
followed at 412 nm and is proportional to the sum of GSH and GSSG present. Tissues 
were homogenized in 10 volumes of 5% (w/v) 5-sulfosalicylic acid at 4 °C. The 
homogenate was centrifuged at 10,000 g for 15 min and the supernatant was assayed for 
GSH by the DTNB-glutathione reductase recycling assay. The 1.0 ml reaction mixture 
contained 190 //I stock buffer (143 mM sodium phosphate and 6.3 mM Na4-EDTA, pH 
7.5), 700 (A 0.248 mg NADPH/ml in stock buffer, 100 1^ 6 mM DTNB and 10 (A sample. 
The assay was initiated by addition of 10 of 266 U glutathione reductase/ml.
Standards were assayed in parallel under the same conditions as tissue samples.
Metallothionein 1MT)
Total tissue MT concentrations were determined by the cadmium-hemoglobin 
affinity assay (140). The high affinity of MT for mercury and cadmium, coupled with
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good stability at low pH and high temperatures, has served as the basis for the 
development of several simple, rapid, and inexpensive metal-binding assays to quantitate 
MT in biological samples. The assay used depended on the ability of heat-precipitable 
protein (crude bovine hemoglobin) to bind and remove excess cadmium that was not 
bound to MT. Tissues were removed, rinsed in ice-cold buffer, and then homogenized in 
4 vol of 10 mM Tris-HCl buffer (pH 7.0), with a glass homogenizer and a teflon pestle. 
The homogenate was centrifuged at 10,000g for 10 min, and the supernatant fraction was 
heated for 2 min in a boiling water bath. The heated samples were then centrifuged at 
10,000g for 2 min to remove precipitated proteins. Heat-denatured supernatant fractions 
were used to measure MT levels. Two hundred microliters of isotope labeled 109Cd 
solution (2 |ig/ml, 1 pCi/ml) was mixed with 200 pi of sample (heat denatured 
supernatant) and allowed to incubate at room temperature for 10 min. Then 100 pi of a 
2% bovine hemoglobin solution was added to the tubes, mixed and heated for 2 min. 
After 2 min in the boiling water bath, the tubes were placed on ice for several minutes, 
centrifuged at 10,000g for 2 min in a microfuge, and another 100 ul aliquot of 2% 
hemoglobin was added. The heating, cooling, and centrifugation were then repeated. A 
500 pi aliquot of the supernatant fraction was carefully removed from the microfuge tube 
and transferred to a clean y -counting tube. The amount of radioactivity in the supernatant 
fraction was then determined by direct y counting. Blank samples were used by replacing 
the tissue sample with the buffer. Also, samples to determine the total radioactivity (200 
pi of buffer added in place of hemoglobin) were run with the assay. The amount of MT 
was calculated and expressed as units of micrograms MT per gram of tissue.
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Determination of Adriamycin cardiotoxicity 
Treatment of experimental animals
Adriamycin solution was prepared from Adriamycin hydrochloride (sigma) 
dissolved in 0.9% saline. For the study of acute toxicity, transgenic mice and normal 
controls (7 weeks old, without regard to sex, because our preliminary studies showed no 
difference in cardiac toxic responses to doxorubicin between males and females) were 
injected introperitoneally (ip) with Adriamycin hydrochloride (Sigma) at 20 mg/kg. Four 
days after receiving the Adriamycin injection, the experimental animals were anesthetized 
ip injection with sodium pentobarbital (65 mg/kg body weight, Vet Labs, Lenexa, KS) 
and cardiotoxicity was determined as described below.
For the chronic study, the dorsal or ventral tail veins of the transgenic and 
nontransgenic control mice were chosen as the site of intravenous injection (iv) of 
Adriamycin. A device to restrain mice for the tail vein injection has been described by 
Boggs [191]. To make the injection easier, the tail was warmed for 5-10 sec in ajar of 
warm water to dilate the tail vein. The tail veins in the FVB (albino) mice are visualized 
as thin red-blue lines coursing along the top (dorsal tail vein) and bottom (ventral tail 
vein). A 26-gauge 1/2-inch needle was used for the injection. Adriamycin saline 
solutions were injected at 5ml/kg of body weight at doses of 9 mg/kg every other week, 
for a total of five injections over 10 weeks (cumulative doses of 45 mg/kg). All animals 
were killed on the second day after the last injection. Adriamycin induced cardiac 
morphological changes were determined by light and electron microscopy.
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Examination of Adriamycin-induced morphological changes 
Both light- and electron-microscopic techniques were employed to examine 
Adriamycin-induced morphological changes as previously described [192]. We have 
found that perfusion of the heart in situ is a much better way to preserve the tissue 
integrity and prevent artifacts. Therefore, the in situ perfusion procedure was used, 
described as follows: into the cardiac apex of the anesthetized mice a cannulated needle 
was inserted about 3 mm, slightly pulled back, with 20 ml syringe filled with wash-out 
solution (6.6 g paraformaldehyde dissolved in 500 ml distilled water; 1.6 ml 50% 
glutaraldehyde; 360 ml 0.2 N sodium cacodylate buffer, pH 7.2-7.4; 0.5 g CaCl3; 0.25 
g A1C13; 1.0 g procaine hydrochloride; add water to make final volume of 1000 ml).
If fresh blood (light red color) comes out smoothly, the needle is in the proper position 
of the left ventricle (needle 25 G 3/8, tubing: silastic medical grade, 0.02" ID and
0.037" OD, CMS#508-002). The right atrium was cut with micro surgical scissors to 
allow blood and solutions to wash out. The heart was perfused with the wash-out 
solution (room temperature) at a flow rate of 5 ml/min for 2-3 min until flowing from 
right atrium became clear. This was followed by perfusion with Karnovsky's fixative 
(10 g paraformaldehyde dissolved in 500 ml distilled water; 50.0 ml 25% 
glutaraldehyde; 360 ml of 0.2 N sodium cacodylate buffer, pH 7.2-7.4; 0.5 g CaCl2; 
0.25 g A1C13; add water to make final volume of 1000 ml) at a rate of 3 ml/min for 10 
min with 20-ml syringe at 4°C. The perfusion quality was indicated by mouse lip, tail 
and eyes becoming pale, liver becoming light gray and hard, and the whole body 
becoming hard. The heart was removed and immersed in pre-cooled (4°C)
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Karnovsky's fixative immediately. Into each tissue vial, two ml of pre-cooled 
Karnovsky's fixative was added (about 10 volumes of tissue blocks). A piece of dental 
wax was put into a petri dish, and adequate fixative was added onto the tissue. The left 
ventricle (LV) and interventricular septum (IVS) were dissected and cut into 1 mm3 
with a razor blade. Six pieces of each LV and IVS were put into each vial filled with 
pre-cooled Karnovsky’s fixative at 4 °C for 90 min, then rinsed 3 times with 0.2 N 
sodium cacodylate buffer, pH 7.4, and post-fixed with 1% ostium tetroxide at 4 °C in 
the dark for 90 min (osmium solution was mixed in the following way: 1 part of 2 % 
osmium tetroxide to 1 part of S-collidine buffer, pH 7.4). The blocks were rinsed 3x 
with distilled H20  and dehydrated with ethanol and propylene oxide according to the 
following schedule: ethanol 50% 5 min; 70% 5 min; 80% 5 min; 95% 10 min; 95% 10 
min; 100% 20 min; 100% 30 min; propylene oxide 20 min for 3 times under hood. 
Then the blocks were infiltrated with propylene oxide/Epon Araldite (2:1) for 1 hour 
(with the cap loose), propylene oxide/Epon Araldite (1:2) for 1 hour, followed by 
Epon Araldite for 1 hour or longer. (Epon Araldite protocol: 10 ml of Araldite 506 
resin, 10 ml of tEpon™-812 Epoxy resin, 24 ml of Dodecenyl Succinic Anhydride and 
0.66 ml of 2,4,6-tri-dimethylamino methyl phenol). Then three blocks were labeled 
and embedded in flat embedding molds with freshly prepared Epon/Araldite and cured 
on the uncovered mold in 55° C oven for 48 hours. Longitudinally and cross 
sectionally oriented myocardial fibers were selected under light microscope (Olympus 
BH-2) on semi-thin sections stained with 1% toluidine blue. Subsequently, ultrathin 
sections obtained with a diamond knife were stained with 2% uranyl acetate and 0.18%
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lead citrate and examined with JEM-100 S transmission electron microscope (JEOL, 
USA, INC) operated at 80 kV.
Myocardial lesions were evaluated on a median section of the whole heart and 
scored as described in the Table 1 according to their severity and extension (192). The 
product of the severity for the extension score gave the total cardiotoxicity score (from 0 
to 10) of each animal, from which the mean total score (MTS) for each animal group was 
calculated. These hearts were scored in a completely blinded fashion. The score was not 
corrected for the background histological damage due to preparation and handling of the 
hearts.
Functional determination
To isolate atria the experimental procedure described by de Jong et al. [193] was 
used with modifications. Both transgenic and control mice of either sex weighing from 
20-3Og were sacrificed under anesthesia by sodium pentobarbital and the entire heart 
was quickly removed. The heart was placed in Dulbecco's calcium-free phosphate buffer 
(pH 7.4) containing NaCl (136.9 mM); KC1 (2.68 mM); KH2P04 (1.47 mM); and 
NaH2P04 (8.0 mM) for 15 min. This incubation causes heart arrest. Atria were 
separated from ventricles and placed in a 20-ml organ bath containing Krebs-Henseleit 
(KH) buffer of the following composition: NaCl (117.5 mM); KC1 (5.6 mM); MgS04 
(1.18 mM); CaCl2 (2.5 mM); NaH2P04 (1.28 mM); NaHC03 (25.0 mM); glucose (11.1 
mM); pH 7.4 gassed with 5% C 02 in 95% 0 2 (20 inmHg). This incubation started at 
ambient temperature, but was gradually warmed to 37°C. Following a 30-min 
stabilization period, a preload tension of 0.25g - 0.5g was applied to each atrial
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preparation. The isolated left atrium was stimulated to contract with square wave pulses 
of 3 msec duration and a voltage of 1.5 times the threshold value. The pluses were 
generated by a Grass S88 stimulator (Quincy, MA) at a fixed frequency of 4 Hz. The 
muscle contractions were recorded isometrically by a Kulite Semiconductor BGG-lOgm 
(Leonia, NS) force transducer and a Gould TA2000 recorder (Lveland, OH). The 
changes of spontaneously frequency (beats/min) recorded from the right atria were used 
to evaluate chronotropic effects.
Table 1. Morphological evaluation of cardiac lesion
Severity degree (a)
1: sarcoplasmic microvacuolization and/or inclusions, interstitial or cellular edema; 
2: as in 1 plus sarcoplasmatic macrovacuolizations or atrophia, necrosis, fibrosis, 
endocardial lesions and thromby;
Extension degree (b)
0: no lesion at all;
.5: less than 10 single altered myocytes on the whole heart section;
1: scattered single altered myocytes;
2: scattered small groups of altered myocytes;
3: spread small groups of altered myocyted;
4: confluent groups of altered myocytes;
5: most of the cells damaged:
Total cardiotoxicity = a x b
To determine whether elevated catalase activity in the transgenic mice provides 
protection against Adriamycin-induced cardiac functional change, a transgenic mouse 
line in which catalase activity is 60-fold higher than normal was selected. After an
49
equilibration period of 30 min with 3 intermittent washings, Adriamycin was added to 
the incubation KH buffer to a final concentration of 100 pm and the contraction of the 
atrium was monitored for 60 min. Time-course effects of Adriamycin on contractile 
force and heart rate were determined using isolated left and right atrium, respectively. 
Contractile force and frequency at the time of Adriamycin addition was set at 
100%.
Lipid peroxidation
Malonaldehyde (MDA) and 4-hydroxyalkenals are important decomposition 
products of peroxides derived from polyunsaturated fatty acids and related esters. It has 
been recognized that measurement of such aldehydes provides a convenient index of lipid 
peroxidation. Because the classical MDA determination by the thiobarbituric-acid 
method (TBA) is influenced by several interferences and its reproducibility is not 
satisfactory (194), a modified assay was used in the present study (195). This modified 
method measures the products of lipid peroxidation, MDA and 4-hydroxyalkenal. A 
commercial kit based on this method was used (LPO-586, Bioxytech S.A., France). The 
LPO-586 method takes advantage of a chromogenic reagent R1 that reacts with MDA 
and 4-hydroxyalkenals at 45 °C. Condensation of one molecule of either MDA or 4- 
hydroxyalkenal with 2 molecules of reagent R1 yields a stable chromophore with 
maximal absorbance at the 586-nm wavelength. Hearts were rapidly excised, trimmed of 
connecting tissue, and washed free of blood with ice-cold saline. They were then blotted 
and weighed. Temperature was maintained at 4 °C throughout the experiment. 1/10 
homogenates (g/ml) were obtained in 20 mM Tris-HCl buffer, pH 7.4. The homogenates
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were centrifuged at 2500g for 10 min at 4 °C. The supernatant was used to assay. For 
each assay, 650 pi of freshly prepared R1 solution and 200 pi sample was added and 
mixed, then 150 pi of methanesulfonic acid R2 was added to start the reaction. The 
reaction mixture was incubated for 40 min in a 45 °C water bath and the absorbance at 
586 nm was measured by using a Beckman Model DU-65 spectrophotometer. Solutions 
S1 and S2 were used to prepare standards for 4-hydroxynonenal and MDA, respectively. 
The level of lipid peroxidation was expressed as nmol of MDA and 4-hydroxynonenal 
per gram tissue.
Creatine phosphokinase (CPK') activity
Serum CPK activity was assayed as described by Oliver (196). CPK catalyzes the 
reaction between creatine phosphate and adenosine diphosphate (ADP), forming creatine 
and adenosine triphosphate (ATP). The ATP formed is utilized to phosphorylate glucose, 
producing glucose-6-phosphate (G-6-P) in the presence of hexokinase (HK). 
Subsequently, G-6-P is oxidized to 6-phosphogluconate (6-PG) in the presence of 
nicotinamide adenine dinucleotide (NAD) by glucose-6-phosphate dehydrogenase (G-6- 
PDH). During this oxidation, an equimolar amount of NAD is reduced to NADH, which 
can be monitored at 340 nm. The rate of change in absorbance is directly proportional to 
CPK activity. A CPK Test kit (CK-20, Sigma) based on this method was obtained from 
Sigma. Blood was collected from the inferior vena cava of the anesthetized animals and 
serum was obtained by a serum separator apparatus (Becton Dickinson and Company, 
Rutherford, NJ). To a 1.0-ml cuvette, 1.0 ml CPK reagent and 0.03 ml sample was added
and incubated at 30° C for 3 min. The increase of absorbance at 340 nm was recorded at
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30-second intervals for a period of 3 minutes. The CPK activity was calculated by using 
the millimolar absorbency of NADH, which is 6.22 at 340 nm and expressed as units of 
enzyme activity per liter serum (U/L). One unit of activity was defined as the amount of 
enzyme which produces one pmol NADH per minute under the conditions of the assay 
procedure.
Statistical analysis
The data obtained was initially analyzed by ANOVA. The differences were further 
analyzed by Duncan's multiple-range test or other appropriate methods. Differences 
between treatments were considered significant at p<0.05.
CHAPTER III
STUDY I: CONSTITUTIVE OVEREXPRESSION OF CATALASE SPECIFICALLY 
IN THE HEART OF TRANSGENIC MICE
Cardiac tissue appears to be particularly sensitive to oxidative damage because the 
enzymes that protect against oxidative damage are markedly lower in the heart than in 
other tissues in the body (161-164). It has been shown that catalase activity in the heart is 
about 2% of that in the liver of the human (160), the mouse (163), and the rat (161). It is 
unknown, however, whether the low catalase activity in the heart is responsible for the 
high sensitivity of this organ to oxidative damage. Although several studies have been 
undertaken to determine the role of catalase in cardioprotection against oxidative injury, 
current approaches using isolated heart perfused with catalase have limited application. 
Exogenously added catalase may not be able to function intracellularly, but may react 
only with H20 2 directly in the perfusion medium. Thus, the relationship between the low 
constitutive catalase activity and the high sensitivity to oxidative stress in the heart has 
not been defined. A unique in vivo model is required to overcome these limitations and 
to precisely determine the role of catalase in protection against oxidative cardiotoxicity.
In this study, a transgenic mouse model in which catalase activity is constitutively 
overexpressed specifically in the heart tissue has been produced. This unique model thus
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transgenic control. As shown in Fig. 8, catalase activity was markedly elevated in the 
transgenic hearts. This elevation ranges from 2- to 650-fold higher than normal among 
the transgenic lines. There was no significant difference in the catalase activity between 
males and females within the same transgenic line (data not shown). The elevated 
catalase activity in the transgenic mice was roughly correlated with the level of mRNA 
for catalase in the transgenic heart as shown in Fig. 7. The results clearly demonstrate 
that the increased catalase activity results from expression of the MyCat transgene. 
Characterization of transgenic mice
It is important to know whether the catalase activity is elevated to the same 
extent in both atria and ventricles. As shown in Fig. 9, the elevated levels of catalase 
in atria and ventricles from 5 representative transgenic lines are the same. These 5 
lines were also used for the experiments described below.
To determine whether the elevated catalase expression is specific to the heart, 
catalase activities in other tissues including liver, lung, and skeletal muscles of the 
transgenic mice were measured. As shown in Fig. 10, catalase activities in all these 
tissues remained the same as controls. There was no alteration in the enzyme activity in 
any of these tissues in the non-transgenic littermates.
We then determined whether other antioxidant enzyme activities in the transgenic 
heart were altered. The enzymatic activities of SOD, GSHpx, and GR were measured in 
the catalase-enriched transgenic hearts. As shown in Table 2, none of these enzyme 
activities were changed. We also measured the concentrations of two important 
nonenzymatic antioxidant components, GSH and MT. There is no alteration in either of
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the two components in the catalase-enriched transgenic hearts (Table 2).
Therefore, characterization of the transgenic mice shows that only catalase, not 
other antioxidant components, is overexpressed specifically in both atria and ventricles of 
the heart. The elevated levels of catalase activity range from 2- to 630-fold higher than 
normal among the 15 transgenic lines. This enzyme activity is not altered in any other 
organs including liver, kidneys, lungs, and skeletal muscles of any of the 5 tested 
transgenic mouse lines. Other antioxidant systems were not altered in the transgenic 
hearts.
Discussion
Heart damage is a severe toxic effect of Adriamycin, resulting in the limitation of 
its application in cancer chemotherapy. Therefore, an understanding of the mechanism 
for the unusual susceptibility of the heart to Adriamycin toxicity is necessary for the 
development of experimental and clinical approaches to improved use of Adriamycin in 
cancer chemotherapy. A possible mechanism for Adriamycin cardiotoxicity is the 
production of oxygen free radicals during its intracellular metabolism. The heart, 
however, has a weak antioxidant system. In particular, the catalase activity is much 
lower in the heart than in other organs. It is therefore postulated that low catalase activity 
in the heart may be a major factor responsible for the high sensitivity. Although several 
studies have been undertaken to determine the role of catalase in cardioprotection against 
oxidative injury, the existing approaches have limited application. In this study, we 
developed the transgenic mouse model in which catalase activity is constitutively 
overexpressed specifically in the heart tissue. This unique model would thus provide an
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Fig. 7. Representative Northern blot analysis of catalase mRNA in the hearts of the 15 
different transgenic mouse lines and the controls. The amount of mRNA detected in each 
line cofficiently correlates with the level of catalase activity in the heart. Three bands 
hybridized with the catalase probe in transgenic samples. Only the smallest band 
corresponds to the expected, fully processed transgenic mRNA. The arrow indicates the
position of the single control band.
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Fig. 8. Catalase activities in the heart from each of the 15 different transgenic mouse 
lines in comparison with that of controls (Cont). Each value is the average of 6
determinations (mean + SD)
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Fig. 9. Comparison of elevated catalase activities in the atria and ventricles in 5 
representative transgenic mouse lines (n=3). There is no significant difference (p>0.1) in 
The catalase activity between the atria and ventricles in any of these transgenic lines.
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Fig. 10. Comparison of catalase activities in the liver, kidney, lung, and skeletal muscles 
rom the left rear leg (Ml) and the stomach (M2) of 5 representative transgenic mouse 
lines sameshown in Fig. 7. The tissues were obtained from control mice (Cont) and 
MyCat transgenic (MyCat+). The data represent mean + SD from 6 control animals and 
representative transgenic lines with 3 animals for each line.
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unequivocal approach to understanding the role of catalase in cardiac protection against 
Adriamycin toxicity.
Table 2. Enzyme activities of SOD, GSHpx, and GR, and concentrations of GSH and 
MT in the hearts of control and MyCat transgenic mice
Control MyCat
SOD (U/g wet wt) 98.6 ±0.3 108.3 ± 13.4
GSHpx (nmol NADPH/min mg protein) 29.8 ±4.4 26.2 ±3.0
GR (nmol NADPH/min mg protein) 14.2 ± 1.7 16.0 ±1.4
GSH (pg/g wet wt) 362.2 ± 11.4 356.0 ± 10.0
MT (pg/g wet wt) 5.1 ±0.6 4.3 ±0.5
The data was obtained from non-transgenic mice (Control, n=6) and 5 representative 
transgenic mouse lines as shown in figure 4 (line 738, 742, 782, 776, 777). Three mice 
were used from each of the 5 lines and the data was pooled together to give the average 
value (MyCat, n=15).
Another unique feature of the model is that among the different transgenic lines, 
catalase activity in the heart is elevated from 2- to 630-fold higher than normal. This 
provides a useful tool to study the catalase activity-dependence of cardioprotection 
against Adriamycin toxicity. It also provides a unique in vivo approach to the importance 
of an optimum balance between SOD and catalase in cellular defense against Adriamycin 
cardiotoxicity. In particular, SOD activity in the heart is about 4-fold lower than that in 
the liver while the catalase activity is about 50-fold lower, suggesting that an imbalance 
between the two enzymes may exist in the heart. Therefore, this experimental model 
would provide a useful tool to address these two important issues of the catalase-involved 
cardioprotection against Adriamycin toxicity.
CHAPTER IV
STUDY II: SUPPRRESSION OF ADRIAMYCIN ACUTE CARDIOTOXICITY BY 
OVEREXPRESSION OF CATALASE IN THE HEART OF TRANSGENIC MICE
Adriamycin is an anthracycline antibiotic and one of the most important 
anticancer agents. It is effective in treatment of acute leukemias and malignant 
lymphomas as well as a number of solid tumors. However, cardiotoxicity is a major 
limiting factor for the clinical use of Adriamycin (26). Studies have suggested that 
Adriamycin may have at least two mechanisms of action that cause cellular damage. One 
mechanism involves generation of oxygen free radicals, the damage from which is 
inhibited by free radical scavengers. This appears to play a major role in the development 
of cardiomyopathy (16, 197). The other mechanism is mediated by the intercalation of 
the drug to DNA and is unaffected by free radical scavengers. This appears to be the 
major determinant of Adriamycin cytotoxicity to tumor cells (16).
As described in the Introduction, catalase is a major enzyme involved in the 
detoxification of hydrogen peroxide (H20 2). This enzyme catalyzes the conversion of 
two molecules of H20 2 to molecular oxygen and two molecules of water. The primary 
physiological function of this enzyme is to detoxify the H20 2 produced as a result of 
peroxisomal aerobic dehydrogenase reactions. The importance of catalase in providing
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protection against extra-peroxisomal H20 2 is not clear. Studies with isolated 
hepatocytes, however, have demonstrated that under conditions of GSH depletion 
catalase functions in metabolism of H20 2 produced by the cytochrome P-450-linked 
monooxygenase system (125). It is thus possible that under conditions of extreme 
oxidative stress, which in most cases involves GSH depletion, catalase may become 
important in providing cytoprotection.
Catalase activities are highest in liver and erythrocytes, relatively high in kidney 
and adipose tissue, intermediate in lung and pancreas, and very low in heart and brain 
(160). It has been shown that catalase activity in the heart is about 2% of that in the 
liver of the human (160), the mouse (163), and the rat (161). Several studies have 
been undertaken to determine the role of catalase in cardioprotection against oxidative 
injuries. Supplementation of perfusion medium with catalase significantly reduced 
ischemia-reperfusion injury to the isolated rat heart by detoxifying H20 2 (165). The 
role of catalase in metabolism of H20 2 in the heart tissue was also tested directly by 
adding H20 2 into perfusion medium (166). Accumulated evidence shows that catalase, 
although present at low levels of activity, functions in detoxification of H20 2 in the 
myocardium.
It is unknown, however, whether the low catalase activity in the heart is 
responsible for the high sensitivity of this organ to oxidative stress. Current 
approaches using the isolated heart perfused with catalase have limited application. 
Exogenously added catalase may not be able to function intracellularly, but may react 
only with H20 2 directly in the perfusion medium. Thus, the relationship between the
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low constitutive catalase activity and the high sensitivity to oxidative stress in the heart 
has not been defined.
In the present study, the transgenic mouse model in which catalase is 
overexpressed only in the heart was used to determine whether catalase elevation 
provides protection against Adriamycin cardiotoxicity. Lipid peroxidation in the 
heart, and serum creatine phosphokinase (CPK) activity were measured in the 
Adriamycin-treated transgenic mice and non-transgenic controls. In addition, the atria 
isolated from the transgenic mice and non-transgenic controls were used to determine 
the effect of catalase on Adriamycin-induced functional changes. The results 
demonstrated that overexpression of catalase in the heart provides protection against 
Adriamycin cardiotoxicity.
Results
Four transgenic lines were selected to determine the effect of elevated catalase 
activity on Adriamycin-induced oxidative damage to the heart. These four transgenic 
lines have cardiac catalase activity about 15-, 60-, 100-, and 200-fold higher than 
normal. Transgenic mice and non-transgenic controls were treated with a single dose 
of Adriamycin at 20 mg/kg. Four days after the treatment, the lipid peroxide products, 
malondialdehyde (MDA) and 4-hydroxyalkenals were determined. As shown in Fig.
11, the level of the lipid peroxidation products was markedly elevated by Adriamycin 
in non-transgenic mice. This toxic effect of Adriamycin was suppressed in the 
transgenic hearts in a catalase activity dependent fashion. The highest protection was 
observed in the hearts expressing this enzyme activity about 60- to 100-fold higher than
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normal. However, the transgenic line overexpressing catalase activity about 200-fold 
higher than normal demonstrated no protection from Adriamycin.
Adriamycin toxicity was also revealed by elevated serum CPK in non-transgenic 
mice (Fig. 12). Catalase overexpression provided essentially the same protection 
against CPK release as it did for lipid peroxidation. Again, the protection was roughly 
activity dependent except for the line with 200-fold overexpression, which failed to 
demonstrate any protection.
Because the loss of protection with 200-fold overexpression of catalase activity 
was unexpected, we performed preliminary studies with 500-fold catalase 
overexpressing mice (line 756). Adriamycin increased MDA levels to 93.1 +. 10.9 
nmol/gm (n=4) in the transgenic heart and 80.6 _+ 2.2 nmol/gm (n=4) in the non- 
transgenic heart. The level of serum CPK was 1.70 ±_ 0.15 U/ml (n=4) in the 
Adriamycin-treated transgenic mice and 1.50 ±_ 0.20 U/ml (n=4) in the Adriamycin- 
treated non-transgenic mice. These preliminary results suggested that 500 fold higher 
levels of catalase may have enhanced Adriamycin-induced lipid peroxidation in the 
heart and CPK release from the heart.
Isolated atria (left and right connected) from transgenic mice overexpressing 
cardiac catalase activity about 60-fold higher than normal were used to determine the 
effect of catalase on Adriamycin-inhibited atrial function. Spontaneous contractions 
were recorded. When Adriamycin was added to the incubation buffer, inhibition of 
both contraction frequency and contractile force occurred. As shown in Fig. 13, the 
catalase overexpressing atrium displayed a marked resistance to the toxic effect of
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Adriamycin. In addition, the function of the transgenic atrium completely recovered 
after removal of Adriamycin, but the normal atrium did not. To precisely determine 
the effect of Adriamycin on contractile force and heart rate, left and right atria were 
separated. The left atrium was paced by a stimulator at a fixed frequency of 4 Hz and 
a voltage of 1.5 times the threshold value. As shown in Fig. 14 and Fig. 15, sixty-fold 
elevation of catalase activity markedly suppressed Adriamycin-induced changes in 
contractile fprce (left atrium) and heart rate (right atrium).
Discussion
Cardiotoxicity has long been recognized as a complicating factor of cancer 
chemotherapy with Adriamycin. There are several hypotheses to explain Adriamycin 
cardiotoxicity. Among these the free radical hypothesis is the most thoroughly 
investigated. Adriamycin undergoes one-electron reduction through a metabolic 
activation caused by NADPH-cytochrome-P-450 reductase, or other flavin-containing 
enzymes (81). This reduction generates Adriamycin semiquinone free-radical. In the 
presence of molecular oxygen, the semiquinone rapidly reduces the oxygen to 
superoxide with regeneration of intact doxorubicin. Superoxide is rapidly converted to 
hydrogen peroxide spontaneously or by superoxide dismutase. The Adriamycin 
semiquinone can then react with the hydrogen peroxide to yield hydroxyl radical (198). 
These highly toxic reactive oxygen species react with cellular molecules including 
nucleic acids, protein, and lipids, thereby causing cell damage. Most supportive 
evidence for this free radical hypothesis has been obtained from in vitro studies 
including reports that: 1) Adriamycin increases lipid peroxidation and free radical
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Fig. 11. Adriamycin-induced lipid peroxidation in the hearts of normal and transgenic 
mice. The levels of malondialdehyde (MDA) and 4-hydroxyalkenals were measured to 
estimate the extent of lipid peroxidation in the tissue. The concentration of the lipid 
peroxides in non-transgenic saline-injected mice (Cont, n=15) was 56.8 nmol/g wet wt. 
Controls for each transgenic mouse line (saline injection only) showed no significant 
difference in the cardiac lipid peroxide level from the non-transgenic controls (data not 
shown). Adriamycin significantly (P<0.05) increased the lipid peroxide level in non- 
transgenic normal mouse hearts (ADR, n=15). Fifteen fold elevation of catalase activity 
in the heart slightly decreased the level of Adriamycin-induced lipid peroxides (line 738, 
n=8). Sixty (line 742, n=10) or 100 fold (line 776, n=10) elevation significantly inhibited 
Adriamycin-induced lipid peroxidation (p<0.05). The level of lipid peroxides in these 
hearts was not significantly different from that in the normal saline-treated hearts. Two 
hundred fold elevation did not significantly decrease the level of lipid peroxides (line
777, n=10).
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Fig. 12. Adriamycin-induced creatine phosphokinase (CPK) release from the heart. 
Serum CPK was measured using a CK-20 kit from Sigma. Sera from the same animals 
treated for determination of lipid peroxidation were collected for the CPK measurement. 
As shown, Adriamycin significantly increased serum CPK level in the non-transgenic 
control mice (ADR). Elevation of catalase in the heart to about 60 (line 742) or 100 fold 
(line 776) higher than normal completely inhibited the increase in the serum CPK level 
(p<0.05). However, elevation of cardiac catalase activity to about 200 fold (line 777) 
higher than normal did not protect against this toxic effect of Adriamycin.
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Fig. 13. Functional changes induced by Adriamycin in the isolated atria (left and right 
connected) from normal and transgenic mice (line 742). The transgenic atrium contains 
catalase activity about 60 fold higher than the normal control. The atria were incubated 
with 100 /xM Adriamycin (final concentration) in the perfusion buffer. Changes in 
spontaneous contraction of the atria were recorded at the times before (0 min) and post 
Adriamycin treatment (10, 20, and 30 min) as shown. This experiment was repeated 5 
times with atria isolated from different animals. The same result was obtained with the
repeated experiments.
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Fig. 14. Effect of catalase elevation on Adriamycin-reduced inotropism. The 
transgenic left atria (line 742) contain catalase activity about 60 fold higher than the 
non-transgenic control and Adriamycin was added into the incubation buffer to a final 
concentration of 100 /iM. The left atria were paced by a fixed frequency of 4 Hz and a 
voltage of 1.5 times the threshold value. Time-course of the effect of Adriamycin on 
the contractile force of transgenic heart and controls was measured. Contractile force 
at the time of Adriamycin addition was set at 100%. This measurement was repeated 
three times with atria isolated from different animals and consistent results were 
obtained.
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Fig. 15. Effect of catalase elevation on heart rate reduced by Adriamycin. The 
transgenic right atria (line 742) contain catalase activity about 60 fold higher than the 
non-transgenic control and Adriamycin was added into the incubation buffer to a final 
concentration of 100 fiM. The spontaneous beating of right atria was recorded. Time- 
course of the effect of Adriamycin on the contraction frequency of transgenic heart and 
controls was measured. Contraction frequency at the time of Adriamycin addition was 
set at 100%. This measurement was repeated three times with atria isolated from
different animals and consistent results were obtained.
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production in the heart tissue (199); 2) free radical scavengers such as N-acetylcysteine 
(200), vitamin E (16,74), superoxide dismutase (74) and catalase (16) decrease the 
severity of Adriamyicn-induced oxidative damage; 3) suppression of antioxidant 
activities enhances Adriamycin toxicity in cultured cardiac cells (201). However, 
contradictory results have been reported. Some in vivo studies have shown that free 
radical scavengers failed to prevent cumulative Adriamycin cardiotoxicity (95,202).
Why have some in vivo studies failed to find antioxidant protection against 
Adriamyicn cardiotoxicity? Under in vivo conditions, three major problems 
complicate data interpretation: 1) it is impossible to maintain constant plasma 
antioxidant concentrations and to accurately predict the target tissue concentrations; 2) 
metabolic activation and inactivation by multiple metabolic organs such as liver and 
kidney would greatly affect the efficacy of the antioxidants; and 3) high molecular 
weight antioxidants such as superoxide dismutase and catalase are unlikely to be 
transported into intracellular compartments. To overcome the shortcomings of these 
earlier in vivo studies, we produced a unique transgenic model. As described in the 
study 1, in this model intracellular catalase activities are maintained at permanently 
elevated levels specifically in the heart of each transgenic line. Other antioxidant 
systems were found to be unaffected in the catalase overexpressing heart. Electron 
microscopic studies (data not shown) demonstrated increased numbers of peroxisomes 
in transgenic hearts, suggesting that a significant amount of elevated catalase is
contained in peroxisomes.
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There are at least two major factors responsible for the selective cardiotoxicity 
of Adriamycin: an unusually high level of drug accumulation (203,204) and weak 
antioxidant defense mechanisms in cardiac muscle cells (161,163). Among the 
important antioxidant enzymes catalase activity in the heart is specially low(160-163). 
The results obtained from this study clearly demonstrate that elevation of catalase 
activity to an optimum level provides protection against Adriamycin-induced cardiac 
injury. This suggests that low catalase activity in the heart is a major factor 
responsible for the high sensitivity of the heart to Adriamycin-induced damage.
Because catalase is a major enzyme that metabolizes H20 2 in the cell and this enzyme 
has no activity to react with Adriamycin and its metabolites, the results thus provide 
direct evidence to support the oxidative injury hypothesis for Adriamycin.
Lipid peroxidation is a major cardiotoxic indicator of Adraimycin, particularly 
under the conditions of acute exposure. It has been found that Adriamycin more 
selectively induces this oxidative damage to the heart relative to other organs such as 
the liver in mice (205). We have determined the lipid peroxide levels in the heart 
induced by Adriamycin as a function of time (days). We found that at the selected dose 
(20 mg/kg) lipid peroxide levels in the heart reach a peak value on the fourth day after 
the drug treatment (data not shown). This peak value coincides with high serum CPK 
activity at the same time, which is in agreement with previous studies (206). Because 
the elevation in serum CPK results from the myocardial cell membrane damage due to 
lipid peroxidation, the increased serum CPK activity has been used as another indicator 
of Adriamyicn-induced heart damage (206,207). The results obtained from this study
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show that elevated catalase activity protects from Adriamycin-induced lipid 
peroxidation, which correlates with the protection against CPK release. In both cases, 
sixty- or 100-fold elevation of catalase activity provides maximum protection.
Functionality of the isolated mouse atrium has been increasingly used as a fast 
screening method for determination of cardiotoxicity induced by Adriamycin (193). 
Usually, the mouse atrium is incubated with the tested compound and changes in 
contractile force and heart rate are recorded as a measurement of cardiotoxicity. It has 
been shown that Adriamycin depresses the functionality of isolated mouse atria (208- 
210). Adriamycin-induced functional changes in the isolated atria were observed in the 
present study. Both contractile force and heart rate were suppressed. Sixty-fold 
elevation of catalase activity markedly depressed this effect of Adriamycin on cardiac 
function. This result demonstrates that Adriamycin-induced cardiac functional 
alterations most likely result from reactive oxygen species and that the severity of the 
functional alterations is associated with catalase levels.
In the present study we found that 200-fold elevation of catalase activity in the 
heart did not provide protection against Adriamycin toxicity and 500-fold elevation 
may even enhance the Adriamycin cardiotoxicity. The same observation has also been 
reported in vitro. For instance, transfection of L cells with a human catalase cDNA 
elevated catalase activity by 100-fold. These catalase-enriched cells, however, were 
more sensitive rather than resistant to the cytotoxicity of paraquat, bleomycin, and 
Adriamycin than the untransfected cells from which they were derived (174). At least 
two mechanisms have been proposed for the increased sensitivity of the high catalase
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containing cells: (1) imbalance between SOD and catalase (172,175); (2) chelation of 
heme iron by catalase and release of iron after degradation of catalase. It has been 
shown that iron-Adriamycin complex is toxic (211). The relevant mechanism for the 
effect observed in this study is unknown. However, the results clearly demonstrated 
that elevation of cardiac catalase activity to an optimal level provides protection against 
Adriamycin acute cardiotoxicity.
CHAPTER V
STUDY III: INHIBITION OF ADRIAMYCIN CHRONIC CARDIOTOXICITY BY 
OVEREXPRESSION OF CATALASE ON THE HEART OF TRANSGENIC MICE
The cardiotoxic effects of Adriamycin can be subdivided into two categories: 
acute effects and chronic effects. The acute effects are characterized by hypotension, 
tachycardia, and various arrhythmias which develop within minutes after iv 
administration and return to normal within a few days. These acute toxic effects are not 
dose-dependent and do not contraindicate further therapeutic application of the drug. In 
contrast, the chronic cardiomyopathy induced by Adriamycin is the major drawback of 
the drug in cancer chemotherapy. This chronic cardiomyopathy is manifested by the 
insidious onset of severe, often fatal congestive heart failure. Therefore, it is important to 
reduce the chronic cardiomyopathy of Adriamycin.
There is growing evidence in the literature that production of oxygen free radicals 
is a primary mechanism in Adriamycin cardiotoxicity. Adriamycin can be reduced by 
cellular flavoenzymes to a semiquinone free radical. This Adriamycin semiquinones then 
gives rise to oxygen free radicals that can initiate cellular damage if they overwhelm the 
antioxidant defense mechanisms. Destruction of toxic reactive oxygen radicals in the 
cytosol and within mitochondria is achieved primarily by three enzymes: glutathione
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peroxidase (GSHpx), superoxide dismutase (SOD), and catalase. It has been found that 
these enzyme activities are lower in the heart than in several other organs, including the 
liver and kidney (163). Addition of catalase and SOD has provided cardioprotection 
under certain pathological conditions(212). In the acute study, the two enzymes given 
together provided better protection than when either enzyme was given alone (213). 
However, the protective activity elicited by SOD and catalase does not extend to long­
term survival. This appears to be related to the instability of the oxoygenously added 
antioxidants in the body, unpredicted pharmacokinetics, and their exclusion from the 
cells. To overcome these limitations, a stable rather than short-term approach is more 
appropriate for these studies.
In this study, we used the unique transgenic mouse model in which catalase was 
constitutively overexpressed in the heart tissues. The role of catalase in protection against 
Adriamycin-induced chronic cardiotoxicity was evaluated by examining morphological 
changes in catalase-enriched transgenic heart and controls treated with Adriamycin.
Results
Three transgenic mouse lines in which catalase are 15-, 60-, and 100-fold higher 
than normal were selected. Transgenic mice and non-transgenic controls were injected iv 
with Adriamycin at a dose of 9 mg/kg every other week, for a total of five injections. On 
the second day after the last injection, the animals were sacrificed and Adriamycin- 
induced cardiac morphological changes were determined by light and electron 
microscopy. The effect of Adriamycin on body weight was measured every week during
Adriamycin treatment.
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The body weight gain of the mice during the 8 weeks of treatment is shown in 
Fig. 16. There was a decrease in mean body weight gain in control mice receiving 
Adriamycin compared to the saline-injected controls after the 8 week of treatment. 
Elevation of cardiac catalase tol5-, 60-, and 100-fold significantly protected against 
Adriamycin-decreased body weight gain. There was no significant difference in body 
weight gains among these three transgenic mouse lines treated by Adriamycin. Mortality 
was encountered only in control animals treated with Adriamycin; about 15% (3 out of 
19) control mice receiving Adiamycin died during the treatment. No deaths were 
observed in the groups of transgenic mice receiving Adriamycin. The results indicate that 
the elevation of catalase provided protection against Adriamycin-induced mortality and 
inhibited the effect of Adriamycin-decreased body weight gain.
Histologic evidence of myocardial damage was evident in mice that died during or 
after Adriamycin treatment. Ventricular myocardium from a control mouse is shown in 
Fig. 17. The lesions observed by light microscopy in myocardium of control mice 
receiving Adriamycin were focal myocyte degeneration, interstitial edema, and interstitial 
and intramyocytic vacuolization (Fig. 18). Focal myocyte degeneration was identified by 
the presence of densely eosinophilic cells lacking cross-striations that gave a positive 
PAS reaction following diastase digestion. The score of the myocardial lesions resulting 
from Adriamycin administration are piesented in Table 3. Fifteen-fold elevation of 
cardiac catalase appeared to protect against Adriamycin-induced cardiotoxicity, but there 
were no significant differences between control and the transgenic groups. However, 60-
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fold and 100-fold elevation of cardiac catalase markedly depressed the morphological 
effects of Adriamycin (p<0.01).
EM studies were performed simultaneously with the above described light 
microscopic studies and results are shown in Figs. 19-22. Myocardial fine structural 
changes were observed in the control mice treated with Adriamycin. Moderate nuclear 
chromatin margination with many pieces of coarse chromatin clumping was observed. 
Mitochondria showed severe swelling with membrane disruption, cristae disappearance 
and matrix clearing. Myelin figures were also observed. Sarcoplasmic reticula and t- 
tubular were slightly dilated. Adriamycin-induced subcellular changes in the transgenic 
mice were much less severe in comparison to that in the control mice. Minor 
mitochondrial swelling was observed with intact mitochondrial membrane and cristae. A 
small degree of myofibrillar lysis with no disruption of the ordered parallel array and no 
myelin figure was found.
Discussion
Adriamycin induced chronic cardiomyopathy is the major drawback of the drug in 
cancer chemotherapy. This chronic cardiomyopathy produces significant morbidity and 
mortality (214). The primary cardiac morphological changes observed in patients with 
chronic Adriamycin treatment are cardiac dilation, myocyte degeneration and atrophy, 
interstitial edema, and fibrosis (215). The degeneration of cardiac muscle cells is 
associated with myofibrillar loss and cytoplasmic vacuolization (215). This chronic 
cardiomyopathy is manifested by the insidious onset of severe, often fatal congestive 
heart failure. Therefore, it is important to reduce the chronic cardiomyopathy.
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Fig .16. Effect of Adriamycin on the body weight gain of transgenic and control mice. 
Transgenic mice and non-transgenic controls were injected iv with Adriamycin at dose of 
9 mg/kg every other week, for total of five injections. Mean body weight gain expressed
at the percentage of initial weight.
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Fig. 17. Light micrograph o f myocardium of non-transgenic control mice.
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Fig. 18. Light micrography of myocardium showing the effect of Adriamycin-induced
cardiotoxicity.
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Table 3. Histological evaluation of the cardiac lesions in control and My Cat transgenic 
mice chronically treated with Adriamycin
MyCat
Control 15-fold 60-fold 100-fold
Severity 1.60 ±0.2 1.3 ±0.05 1.14 ±0.06 1.04 ±0.04
Extension 1.72 ±0.06 1.60 ±0.05 1.00 ±0.04* 0.97 ±0.11*
Total cardiotoxi­
city score
2.77 ± 0.40 2.10 ± 0.13 1.14 ±0.08* 1.00 ±0.08*
*p<0.01 with respect to control mice.
A recent review by Herman et al.(216) has extensively summarized current 
existing approaches to reduce the cardiotoxicity of anthracyclines. These attempts to 
ameliorate anthracycline cardiotoxicity include: (1) decreasing myocardial 
concentrations of anthracyclines and their metabolites, (2) developing less cardiotoxic 
analogues, and (3) concurrently administering other drugs that will block or overcome 
the toxic effects of anthracyclines on the myocardium.
To decrease myocardial concentrations of anthracyclines clinicians have applied 
methods including alternative dosing regimens, slowly infusing the drug to keep plasma 
concentrations low, and/or binding the drug to carrier molecules to decrease the 
availability of the drug to myocytes. Alternatively, a considerable effort has been 
directed to the synthesis and development of new compounds that will retain significant 
anticancer activity while decreasing cardiac toxicity. Finally, many substances have 
been tested experimentally as potential cardiac protective agents which can be 
concurrently administered with anthracyclines. These substances include free
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Fig. 19. Electron micrograph o f myocardium of non-transgenic control mice. Cross-
section, X 6000.
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Fig. 20. Electron micrograph of myocardium of non-transgenic control mice.
Longitudinal-section, X 6000.
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Fig. 21. Electron micrograph showing myocardial morphological changes induced 
bychronic treatment of Adriamycin. Cross-section, X 6000.

102
Fig. 22. Electron micrograph showing myocardial morphological changes induced by 
chronic treatment of Adriamycin. Longitudinal-section, X 6000.
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radical scavengers, calcium channel blockers, histamine and catecholamine blockers, 
cardiac glycosides, carnitine, and EDTA derivatives. These approaches, however, 
have achieved limited success.
Although the mechanism of Adriamycin-induced cardiotoxicity has not yet been 
established, recent evidence suggests that Adriamycin forms reactive oxygen free radical 
species that may oxidize cellular components such as cell membrane components leading 
to cardiomyopathy. Adriamycin produces free radicals that damage myocardial tissue by 
nonspecific oxidation of membrane and cytosol molecules, eventually leading to cell 
death. Destruction of toxic reactive oxygen radicals in the cytosol and within the 
mitochondria is achieved primarily by three enzymes: glutathione peoxidase (GSHpx), 
superoxide dimutase (SOD), and catalase. It has been found that these protective enzyme 
activities are lower in the heart than in several other tissues (163). Addition of catalase 
and SOD has provided cardioprotection under certain pathological conditions, including 
myocardial ischemia. The effects of treatment with two of these protective enzymes on 
Adriamycin toxicity were elucidated in mice and rats (212). Increased survival of the 
mice treated with SOD (16 mg/kg, ip) after a single 13.5 mg/kg (ip) dose of Adriamycin 
(45% survival with SOD and Adriamycin campared to 30% survival with Adriamycin 
alone) was observed. At higher Adriamycin dose (15 mg/kg) survival increased from 
12% (Adriamycin alone) to 40% (SOD and Adriamycin). In a second study rats were 
dosed with Adriamycin given either chronically (4 mg/kg/wk for 3 weeks) or acutely (a 
single dose of 10 mg/kg) and simutaneously treated with catalase (1 mg/kg/day), SOD (1 
mg/kg/day) or both. The SOD decreased and catalase increased survival in animals given
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the 3 doses of Adriamycin. Survival increased further when SOD and catalase were 
given together. Some attenuations in myocardial alterations also occurred. In the acute 
study, the two enzymes given together provided better protection than when either 
enzyme given alone (213). However, the protective activity elicited by SOD and catalase 
does not include long-term survival and appears to be related to many unstable factors as 
described before. To overcome the shortcomings of these in vivo studies, we used the 
unique transgenic mouse model that was produced in this laboratory. As described in 
Study 1, in this model intracellular catalase activities are maintained at permanently 
elevated levels which are specific to the heart of each transgenic line. This unique model 
provides an unequivocal experimental approach to precisely determine the role of catalase 
in myocardial protection against Adriamycin chronic toxicity in vivo.
The results of this investigation showed that the FVB mice are sensitive to the 
cardiotoxic effects of repeated iv injections of low dosages of Adriamycin. The 
cumulative dosage of 45 mg/kg reduced body weight gain and produced typical 
anthracycline cardiomyopathy in the control mice. The myocardial lesions described in 
this investigation were similar to those that occured with chronic Adriamycin 
administration in humans (22), rabbits (41,217), and rats (218). The transgnenic mice in 
which catalase was elevated to 60-, and 100-fold higher than normal showed markey 
resistance to the reduction of body weight gain induced by Adriamycin. These transgenic 
mice were also protected from Adriamycin induced cardiac morphological changes.
These results demonstrated that Adriamycin-induced cardiomyopathy most likely 
resulted from enhanced generation of reactive oxygen free radicals and toxic lipid
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peroxidation and the severity of the morphological alteration was associated with cardiac 
catalase levels. The data also suggested that the transgenic mouse model provided an 
ideal tool for the chronic studies regarding the role of antioxidants in protection against 
Adriamycin cardiotoxicity.
CHAPTER VI
STUDY IV : REPRESSION OF HYPOXIA-REOXYGENATION INJURY IN THE 
CATALSE OVEREXPRESSION HEART OF TRANSGENIC MICE
Ischemia-reperfusion causes depressed myocardial functional changes associated 
with deleterious morphological alterations, leading to heart failure and cell death (219). 
Mechanisms by which this injury occurs are not well defined. Studies using antioxidants 
such as superoxide dismutase (SOD) and catalase suggest that oxidative stress and burst 
of free radical production are important mediators of the myocardial damage (220). The 
available evidence at present indicates that reperfusion arrhythmias and myocardial 
stunning result at least in part from oxygen radicals (221, 222). Myocardial infarction or 
cell death may also relate to reactive oxygen radicals (223).
Because catalase is a major enzyme involved in the detoxification of hydrogen 
peroxide (H20 2) and the activity of catalase per g tissue in the heart is very low, the high 
sensitivity of the heart to hypoxia-reoxygenation may result from its less efficient 
hydrogen peroxide detoxification system. Several studies have been undertaken to 
determine the role of catalase in cardioprotection against oxidative injuries. 
Supplementation of perfusion medium with catalase significantly reduced ischemia- 
reperfusion injury to the isolated rat heart by detoxifying H20 2 (165). The role of catalase
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in the metabolism of H20 2 in the heart tissue was also tested directly by adding H20 2 into 
perfusion medium (166). Accumulated evidence shows that catalase, although present at 
low levels of activity in the heart, functions in detoxification of H20 2 in the myocardium. 
However, current approaches using the isolated heart perfused with catalase have limited 
application. Exogenously added catalase may not be able to function intracellularly, 
because of its exlusion from the cells due to its high molecular mass. Furthermore, it is 
difficult to prolong the catalase perfusion procedure, if that should be an appropriate 
approach. Thus, the relationship between the low constitutive catalase activity and the 
high sensitivity to oxidative stress in the heart cannot be defined.
The transgenic mouse model in which catalase is overexpressed only in the heart 
would be a useful tool to address the role of catalase in cardiac protection against 
hypoxia-reoxygenation injury to the heart.. In this study, we determined the effect of 
catalase elevation on hypoxia-reoxygenation induced damage to isolated atria.
Functional alterations and morphological changes of the atria under hypoxia- 
reoxygenation conditions were examined. The results demonstrate that overexpression of 
catalase in the heart provides protection against hypoxia-reoxygenation induced cardiac 
injury.
Results
Spontaneous contractions of the isolated atria (combined left and right) were 
recorded when a mixture of 95% 0 2-5% C02 was bubbled into the perfusion chamber.
As shown in Fig. 23, transgenic atrium and normal control displayed similar contractions 
at time 0. Hypoxia was then induced by gassing the perfusion buffer with 95% N2-5%
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C 02 (20 mmHg) at 37°C for 240 min. Reoxygenation was done by gassingwith 95% 0 2- 
5% C 02 (20 mmHg). The contractile force and frequency of both atria were gradually 
suppressed by hypoxia. However, the transgenic atrium showed marked resistance to this 
hypoxia-induced functional change. The transgenic atrium extensively recovered its 
normal contraction upon reoxygenation. However, the normal atrium displayed abnormal 
contractions, arrhythmia, a typical reperfusion injury.
To precisely determine the effect of elevated catalase on atrial functional 
alterations induced by hypoxia-reoxygenation, left atrium was separated from right 
atrium. Cardiac inotropy (contractile foice) and chronotropy (contraction rate) were 
recorded from left and right atria, respectively. As shown in Fig. 24 and Fig. 25, both 
contractile force and frequency were dramatically depressed under hypoxia in either 
normal or transgenic mouse atria. However, the transgenic atria showed significant 
resistance against hypoxia-induced decrease in frequency Upcn reoxygenation, both 
force and frequency partially recovered. The transgenic atria, however, displayed much 
better recovery than the normal atria. Particularly, a gradual decrease in frequency with 
arrhythmia (as shown in Fig. 23) was observed in the normal atria after reoxygenation, 
while a stable unchanged frequency remained in the transgenic atria.
Morphological studies showed that the myocardial cells of both left and right atria 
(Figs. 26-31) subjected to hypoxia and reoxygenation in normal FVB mice showed 
margination and coarse clumping of the chromatin, mitochondrial swelling and 
disappearance of crstae, often leaving the remnants of the original structure and myelin 
figures. The matrix of the mitochondria became translucent. Some myocardial cells
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showed marked cell swelling, the sarcolemma exhibited large empty bleb-like spaces and 
small defects in plasma membrane. The basal lamina appeared to be separated from the 
surface bilayer membrane. Vesiculation and disruption of the sarcoplasmic reticulum 
were obvious. Hypoxic vacuoles were frequently observed. The myofibril between 
contraction bands showed partially broken Z-line and a wispy I band. However, in 
catalase-transgenic mouse atria, these changes above were only rarely seen in either left 
or right atrium.
Discussion
Myocardial injury due to ischemia-reperfusion has been extensively studied. This 
injury results at least in part from reactive oxygen radicals, although the exact mechanism 
by which the pathogenesis occurs is at present unknown. Recent studies have shown 
myocardial protection against ischemia-reperfusion injury and changes in gene 
expression occur after whole body heat stress (224-228). For example, reduced infarct 
size in vivo (226,229) and in vitro (227) due to ischemia-reperfusion has been shown 24 
hr after whole body temperature elevation to 42°C for 15 min. This whole body heat 
stress procedure also enhanced postischemic contractile function in vitro (224, 225,228). 
The exact nature of this induced protection is unclear. A number of studies (224,225), 
however, demonstrated that alterations in myocardial antioxidant systems may be 
involved in this process.
I l l
Fig. 23. Functional changes induced by hypoxia-reoxygenation in the isolated atria from 
normal and transgenic mice. The transgenic atrium contains catalase activity about 60- 
fold higher than normal. The atria were incubated under the condition described in the 
Materials and Methods. At time 0, hypoxia was introduced and lasted for 60 min, then 
oxygen was re-introduced and spontaneous contraction was recorded for the entire period 
of hypoxia-reoxygenation. This experiment was repeated five times with the atria 
isolated from different animals and the same result was obtained as the representative.
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Fig. 24. Effect of catalase elevation (60-fold higher than normal) on reduction in force 
induced by hypoxia and reoxygenation. The left atrium of transgenic and non-transgenic 
mice were subjected to 60 min hypoxia and 240 min reoxygenation. The left atrium was 
paced by a fixed frequency of 4 Hz and a voltage of 1.5 times the threshold value. Time- 
course of the effect of hypoxia-reoxygenation on the contractile force of transgenic heart 
and controls was measured. Contractile force at the time that hypoxia was introduced 
was set at 100%. This measurement was repeated 6 times with atria isolated from 
different animals and the data are presented as mean + SD values.
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Fig. 25. Effect of catalase elevation (60-fold higher than normal) on reduction in heart 
rate induced by hypoxia and reoxygenation. The right atrium of transgenic and non- 
transgenic mice was subjected to 60 min hypoxia and 240 min reoxygenation. 
Spontanous contraction was recorded. Time-course of the effect of hypoxia- 
reoxygenation on the contraction frequency of transgenic heart and controls was 
measured. Contraction frequency at the time that hypoxia was introduced was set at 
100%. This measurement was repeated 6 times with atria isolated from different animals 
and the data are presented as mean + SD values.
1 1 6
Time (Min)
117
Fig. 26. Electron micrograph of left atrium of non-transgenic control.
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Fig. 27. Hypoxia-reoxygenation induced myocardial morphological changes o f left
atrium of non-transgenic control.
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Fig. 28. Hypoxia-reoxygenation induced myocardial morphological changes o f left
atrium of transgenic mouse.
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Fig. 29. Electron micrograph of right atrium of non-transgenic control.
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Fig. 30. Hypoxia-reoxygenation induced myocardial morphological changes of right 
atrium of non-transgenic control.
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Fig. 31. Hypoxia-reoxygenation induced myocardial morphological changes of right
atrium of transgenic mouse.
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Catalase is increased within the myocardium 24 hr after whole body heat stress 
(225). This enzyme is highly relevant to protection because of its role in detoxification of 
hydrogen peroxide. Supplementation of perfusion medium with catalase significantly 
reduced ischemia-reperfusion injury to the isolated heart (165), and inhibition of catalase 
can at least partially abolish post-heat stress protection when contractility is used as the 
endpoint of injury (14).
Catalase is, however, not the only protein that is elevated after heat stress. An 
inducible member of the hsp70 family shows marked changes 24 hr after heat stress (224- 
229). Numerous studies have suggested the possible involvement of HSP70 in 
myocardial protection. For example, elevated levels of the highly inducible member of 
the HSP70 family were associated with improved post-ischemia recovery (230-232) and 
with reduction in infarct size in hearts (233). There appears to be a correlation between 
the amount of the inducible HSP70 and the extent of myocardial protection (234). A 
more direct demonstration of the involvement of the inducible HSP70 in myocardial 
protection against ischemic injury comes from two recent studies using transgenic mice 
overexpressing the inducible HSP70 (235,236). Both studies showed a marked resistance 
to ischemia-reperfusion injury in the isolated hearts from the HSP70 overexpressing 
transgenic mice.
In the present study, direct evidence regarding the importance of catalase in 
myocardial protection against hypoxia-reoxygenation was obtained. We took advantage 
of elevation of catalase specifically in both atria and ventricles of the transgenic mice and 
directly monitored atrial functional alteration under hypoxia-reoxygenation. Importantly,
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the isolated atria allowed precise determination of the effects of hypoxia and 
reoxygenation on heart rate and contractile force. The results demonstrated that hypoxia- 
reoxygenation reduces contractile force and frequency in the isolated atria. 
Reoxygenation resulted in arrhythmia, a typical reperfusion injury observed in the heart 
both in vitro and in vivo. The catalase overexpressing atrium displayed a marked 
attenuation in the hypoxia-reoxygenation induced reduction of contractile force and 
contraction frequency, and abolished the reoxygenation-induced arrhythmia. 
Corresponding to these protective effects on functional alterations induced by hypoxia- 
reoxygenation, catalase overexpression in the heart also markedly suppressed the 
morphological changes as examined by electron microscopy.
Other experimental approaches have involved the use of catalase to study its role 
in cardiac protection against ischemia-reperfusion injury. Most of these studies either 
supplemented catalase in vivo or added catalase in perfusion buffer in vitro. Three major 
problems complicate data interpretation from these studies: 1) it is impossible to maintain 
constant plasma antioxidant concentrations and to accurately predict the target tissue 
concentrations; 2) metabolic activation and inactivation by multiple metabolic organs 
such as liver and kidney would greatly affect the efficacy of the antioxidant; and 3) high 
molecular weight catalase is unlikely to be transported into intracellular compartments.
To overcome the shortcomings of these earlier studies, we utilized the unique transgenic 
model in the present study. In this model intracellular catalase activities are maintained 
at permanently elevated levels specifically in the heart without alterations in any other 
antioxidant systems. The experiments with the card'ac catalase overexpressing
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transgenic mouse heart thus strongly suggest that an elevated level of catalase plays a role 
in cell protection against reactive oxygen induced damage. This study also suggests that 
low catalase activity in the heart is a major factor responsible for the high sensitivity of 
the heart to ischemia-reperfusion injury. In addition, because catalase is a major enzyme 
that metabolizes H20 2 in the cell and this catalase activity is quite specific, the results 
thus provide direct evidence to support the oxidative injury hypothesis for ischemia- 
reperfusion.
In summary, catalase overexpression in the heart of transgenic mice inhibited 
hypoxia-reoxygenation induced reduction in contractile force and heart rate, and 
eliminated reoxygenation-induced arrhythmia. The catalase overexpressing transgenic 
atria were also highly resistant to hypoxia-reoxygenation induced morphological 
alterations as examined by electron microscopy. The results thus provide direct evidence 
that catalase is significantly involved in cellular protection against hypoxia-reoxygenation 
cardiotoxicity.
CHAPTER VII
SUMMARY OF DISCUSSION
Adriamycin is widely used in clinical medicine for cancer chemotherapy. It has a 
broad range of antitumor activities including soft tissue sarcomas, breast cancer, small 
cell carcinoma of the lung, and acute leukemias. Unfortunately, the clinical use of 
Adriamycin has been limited by its undesirable side effects, especially cardiotoxicity.
The cumulative dose-dependent cardiomyopathy limits the total dose of Adriamycin that 
can be administrated in the treatment of neoplastic diseases(30). The prevention of 
Adriamycin cardiotoxicity without interferences with the drug's antitumor activity would 
be of considerable consequence in achieving additional therapeutic benefit from this 
agent.
Adriamycin-induced perturbation in myocardial cells includes mitochondrial 
lesions, disruption of myofibrils, degeneration of Z-band, and eventually myocyte 
dropout (22,41). These lesions are accompanied by or eventually lead to myocardial 
dysfunction, which will manifest as heart failure in some patients. Although these 
morphological and functional descriptions of Adriamycin's cardiotoxicity have been 
known for many years, the mechanism of production of these lesions and the reason for 
the selective toxicity to the heart remain unknown. One of the most likely mechanisms 
for the cytotoxicity of Adriamycin is the production of free radicals in the heart which 
results in lipid peroxidation, a cause of Adriamycin-induced cardiomyopathy (199). This
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free radical mechanism has been supported by the evidence including reports that: 1) 
Adriamycin increases lipid peroxidation and free radical production in the heart tissue 
(199); 2) free radical scavengers such as N-acetylcysteine (200), vitamin E (16,74), 
superoxide dismutase (74) and catalase (16) decrease the severity of Adriamycin- 
induced oxidative damage; 3) suppression of antioxidant activities enhances Adriamycin 
toxicity in cultured cardiac cells (201). However, contradictory results have been 
reported. Some in vivo studies have shown that free radical scavengers failed to 
prevent cumulative Adriamycin cardiotoxicity (95,202).
Intact cells regulate redox state by several enzymatic processes in which 
glutathione peroxidase (GSHpx) and catalase are of major importance in protecting cells 
from oxidative damage by free radicals. However, both enzymes are low in the heart, in 
particular, catalase activity in the heart is about 2% of that in the liver. The relative 
deficit in cardiac catalase may be a factor responsible for the high sensitivity of the heart 
to oxidative damage. This hypothesis has been continually tested using isolated hearts 
and other in vitro models (165-168). But current approaches provide only in vitro 
understanding of Adriamycin acute cardiotoxcity. To provide an unique in vivo model 
for studying both acute and chronic Adriamycin cardiotoxicity, we developed a 
transgenic mouse model in which catalase was overexpressed specifically in the heart 
tissue. Characterization of the transgenic mice shows that only catalase, not other 
antioxidant components, was overexpressed specifically in the heart, in both atria and 
ventricles. This enzyme activity was not altered in any of other organs including liver, 
kidneys, lungs, and skeletal muscles of any of the five tested transgenic mouse lines.
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The model is ideal to determine the role of catalase in protection against Adriamycin- 
induced heart injury.
Another unique feature of the model is that among the different transgenic lines, 
catalase activity in the heart is elevated from 2- to 630-fold higher than normal. This 
certainly provides a useful tool to study the catalase activity-dependence of 
cardioprotection against Adriamycin toxicity. It also provides a unique in vivo 
approach to the importance of an optimum balance between SOD and catalase in 
cellular defense against Adriamycin cardiotoxicity. In particular, SOD activity in the 
heart is about 4-fold lower than in the liver while the catalase activity is about 50-fold 
lower, suggesting that an imbalance between the two enzymes may exist in the heart.
Chronic cumulative cardiotoxicity is the limiting factor for the clinical 
application of Adriamycin. However, current approaches have limitations to address 
the relationship between antioxidants and Adriamycin toxicity. Maintaining a constant 
level of exogenously added antioxidants in the heart is impossible. Moreover, high 
molecular weight antioxidants such as catalase can not be transported into cells. As 
described in study 3, the model thus provided a unique approach for the chronic studies 
regarding the role of antioxidants in protection against Adriamycin cardiotoxcity.
We have determined the effects of varying catalase activities on the acute and 
chronic toxicities of Adriamycin by examining biochemical, morphological, and 
functional alterations of the hearts.
Creatine phosphokinase (CPK) is primarily located in skeletal muscles and heart
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muscle. Damage to these tissues results in the release of increased levels of CPK into 
the blood. Cardiac muscle injury following myocardial infarction results in a rise in 
serum CPK activity, reaching a peak of 7- to 12- times the upper limit of normal within 
18 to 30 hours. Therefore, measurement of serum CPK activity is used as a diagnostic 
tool to detect myocardial infarction and various forms of muscle disease. Elevation of 
serum CPK has been used as an indicator of Adriamycin-induced heart damage 
(206,207). We found that at the selected dose (20 mg/kg ip) serum CPK activity was 
significantly increased in the control mice. The elevation of serum CPK activity was 
associated with increased lipid peroxidation levels. Trangenic mice in which catalase 
activities are 60- and 100-fold higher than normal provided protection against 
Adriamycin-induced CPK release from the hearts. However, the transgenic line 
overexpressing catalase 200 fold higher than normal demonstrated no protection from 
Adriamycin.
Isolated atria from non-transgenic mice and transgenic mice overexpressing 
cardiac catalase 60-fold higher than normal were used to determine the effect of 
Adriamycin on atrial function. Adriamycin suppressed both contractile force and 
contraction frequency of control heart. Sixty-fold elevation of catalase activity 
markedly depressed this functional effect of Adriamycin. This result demonstrates that 
Adriamycin-induced cardiac functional alterations most likely result from reactive 
oxygen species and that the severity of the functional alterations is associated with 
catalase levels.
Adriamycin-induced cardiac morphological changes in animal models and
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human patients have been well documented (214-216). The primary cardiac 
morphological changes include cardiac dilation, myocyte degeneration and atrophy, 
intestitial edema, and fibrosis (215). The degeneration of cardiac muscle cells is 
associated with myofibrillar loss and cytoplasmic vacuolization (215). Electron 
microscopic studies have shown that the vacuolization of the cytoplasm is mainly due to 
pronounced swelling of the tubules and cisterns of the sarcoplasmic reticulum (216). 
The mitochondria have been found to show a variety of changes, including swelling, 
disruption, alterations in the density of the matrix, and formation of myelin figures.
We determined the effect of elevated catalase activities in the heart of trangenic mice 
on Adriamycin-induced morphological changes and found that 60-fold and 100-fold 
elevation of cardiac catalase attenuated the morphological changes in both acute and 
chronic treatment of Adriamycin.
It has been shown that Adriamycin undergoes one-electron reduction through a 
metabolic activation caused by NADPH-cytochrome-P-450 reductase, or other flavin- 
containing enzymes (11). This reduction leads to a free-radical semiquinone, which in 
turn can generate reactive reduced oxygen species such as superoxide anion (0 2), 
hydrogen peroxide (H20 2), and hydroxyl radical (HO ) (81). These highly toxic 
species may react with cellular molecules including nucleic acids, protein, and lipids, 
thereby disrupting them. More importantly, the oxygen radical chain reaction leads to 
lipid peroxidation at the plasma membrane, which is considered to be responsible for 
lethal membrane damage (238). Strong evidence is presently available for the 
involvement of oxidative membrane damage in the cardiac toxicity of Adriamycin
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(197). Therefore, we determined that the effect of elevated catalase activities on 
Adriamycin induced lipid peroxidation in the heart with the acute treatment. We found 
that at the selected dose (20 mg/kg) lipid peroxide levels in the heart reach a peak value 
on the fourth day after the drug treatment (data not shown). This peak value coincides 
with high serum CPK activity, which is in agreement with previous studies (206). The 
elevated catalase activity protects from Adriamycin-induced lipid peroxidation, which 
correlates with the protection against CPK release. Sixty- or 100-fold elevation of 
catalase activity provides maximum protection. The results obtained from this study 
suggests that elevation of cardiac catalase provides protection against Adriamycin 
cardiotoxicity by the mechanism of detoxification of oxidative stress and inhibiting 
lipid peroxidation.
The results obtained from our studies clearly demonstrated that elevation in 
catalase activity to an optimum level provided protection against Adriamycin-induced 
cardiac injuries. Low antioxidant capacity in the heart is therefore a major factor 
responsible for the high sensitivity of the heart to Adriamycin-induced damages. The 
results not only illustrate the importance of catalase in cardiac protection against 
Adriamycin toxicity, but also further suport the oxidative injury hypothesis of 
Adriamycin.
The relative deficit in the antioxidant activity of the heart may be responsible 
for its unusual sensitivity to not only Adriamycin but also other toxic agents. The 
catalase-enriched transgenic mouse model would provided a valuable experimental 
approach to understanding mechanisms of other cardiac oxidative damage. Myocardial
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injury due to ischemia-reperfusion has been extensively studied. Although the exact 
mechanism by which the pathogenesis occurs is unknown, this injury results at least in 
part from reactive oxygen radicals. There is argument regarding whether low catalase 
activity in the heart generally makes the heart more sensitive to a variety of ischemia- 
reperfusion injuries. Our transgenic mouse model was used to determine the effect of 
elevated catalase on hypoxia-reoxygenation induced damage to isolated atria.
Functional alterations and morphological changes of the atria under hypoxia- 
reoxygenation conditions were examined. The results demonstrated that the catalase 
overexpressing atrium displayed a marked attenuation in the hypoxia-reoxygenation 
induced reduction of contractile force and contraction frquency. Corresponding to these 
protective effects on functional alterations induced by hypoxia-reoxygenation, catalase 
overexpression in the heart also markedly suppressed the morphological changes as 
examined by electron microscopy. The results thus provide direct evidence that catalase 
is important in cellular protection against hypoxia-reoxygenation cardiotoxicity. The 
model is thus ideal to study the mechanism of many cardiac oxidative injuries.
CHAPTER VIII
FUTURE AREAS OF RESEARCH
In our studies we found that 200 fold elevation of catalase activity in the heart 
did not provide protection against Adriamycin toxicity and 500 fold elevation even 
enhances the Adriamycin cardiotoxicity. The same observation has also been reported 
in vitro. For instance, transfection of L cells with a human catalase cDNA elevated 
catalase activity by 100-fold. These catalase-enriched cells, however, were more 
sensitive rather than resistant to the cytotoxicity of paraquat, bleomycin, and 
Adriamycin than the untransfected cells from which they were derived (45). At least 
two mechanisms have been proposed for the increased sensitivity of the high catalase 
containing cells: (1) imbalance between SOD and catalase (46-48); (2) chelation of 
heme iron by catalase and release of iron after degradation of catalase. It has been 
shown that iron-Adriamycin complex is toxic (49). The relevant mechanism for the 
effect observed in our mice is unknown. Therefore, we will determine why the very 
high level of cardiac catalase does not provide protection against, or even enhances 
Adriamycin cardiotoxicity.
Both catalase and GSHpx are important in detoxification of H20 2. GSHpx is 
also capable of reducing organic hydroperoxides. The importance of catalase in 
providing protection against extra-peroxisomal H20 2 is not clear. Studies with isolated 
hepatocytes, however, have demonstrated that under conditions of GSH depletion
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catalase functions in metabolism of H20 2 produced by the cytochrome P-450-linked 
monooxygenase system [11]. It is thus possible that under conditions of extreme 
oxidative stress, which in most cases involves GSH depletion, catalase may become 
increasingly important in providing protection against xenobiotic-induced H2Oz 
production. In future, we will determine whether the elevated catalase activity can 
replace the role of GSHpx in cellular defense against oxidative stress and Adriamycin- 
induced injury by using both primary cell cultures and whole animal studies.
As mentioned in the introduction, catalase is localized mostly within the 
peroxisomal compartment. At present, we do not know whether the transgene-directed 
expression of catalase activity is targeted to the peroxisome, cytosol, or other 
compartments. It is worthwhile to determine the localization of the overexpressed 
catalase activity in the cell. Similarly, it is important to know which cell types in the 
heart are targeted to express the transgenic catalase. Polyclonal antibody to catalase is 
commercially available. Therefore we will use light-microscopic immunoperoxidase 
and electron-microscopic immunogold techniques to identify both the cell types to 
which the catalase is expressed and the subcellular localization of the catalase in the 
myocardium tissue. The significance of subcellular localization and the cell type of 
expression of the catalase in the protective response to Adriamycin will thus be
elucidated.
APPENDIX
ADP Adenosine 5'-diphosphate
ADR Adriamycin
ATP Adenosine 5'-triphosphate
CPK creatine phosphokinase
DTNB 5,5'-dithiobis (2-nitrobenzoate)
EDTA ethylenediaminotetraacetic acid
g grams
GR glutathione reductase
GSH glutathione (reduced form)
GSHpx glutathione peroxidase
GSSG glutathione disulfide
1 liter
M Molar
mg milligrams
min minutes
ml milliliter
mM millimolar
mol mole
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mmol millimole
MT metallothionein
NAD, NADH Nicotinamide adenine dinucleotide and the reduced form
NADP, NADPH Nicotinamide adenine dinucleotide phosphate and the reduced 
form
nM nanomolar
nmol nanomole
PCR Polymerase chain reaction
SDS sodium dodecyl sulfate
sec seconds
SOD superoxide dismutase
rpm revolutions per minute
Tris tris hydroxymethylaminomethane
Pg microgram
Pi microliter
pM micromolar
pmol micromole
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